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ZUSAMMENFASSUNG 
Die PEST-domänenreiche Tyrosinphosphatase PEP ist eine cytoplasmatische 
Tyrosin-Phosphatase, die die Funktion von Immunzellen einschließlich der 
von Mastzellen reguliert. Mastzellen sind wichtige Effektorzellen, die die 
allergische Reaktion als Antwort auf ein Antigen auslösen. Die 
antigenvermittelte Aktivierung von Mastzellen führt zu der Freisetzung von 
gespeicherten Entzündungsmediatoren, die als Degranulation bezeichnet 
wird. Außerdem initiiert die Mastzellaktivierung die de novo Synthese und 
Freisetzung von Lipid-Derivaten und die Synthese und Freisetzung von 
Zytokinen/Chemokinen. Frühere Studien zeigen, dass PEP eine positive 
regulatorische Rolle in der Mastzelldegranulation einnimmt, da die 
Degranulation von aus Knochenmark gewonnenen Mastzellen (BMMCs) von 
PEP-/- Mäusen, verglichen mit PEP+/+ BMMCs, geschwächt ist. Es war 
allerdings bislang unbekannt ob PEP auch noch weitere Mastzellfunktionen 
wie die Lipidmediator-Synthese und Genexpression von 
Zytokinen/Chemokinen beeinflusst. Weiterhin wird PEP durch 
Dexamethason, einem steroidalen entzündungshemmenden Glucocorticoid, 
das zur Behandlung von Allergien eingesetzt wird, hochreguliert. Die Rolle 
von PEP bei der antiallergischen Wirkung von Glucocorticoiden (GC) war 
jedoch noch nicht bekannt.  
Unter Verwendung von BMMCs von PEP+/+ und PEP-/- Mäusen in RNA-
seq Experimenten wurde gezeigt, dass aktivierte PEP-/- BMMCs eine 
herabgesetzte Zytokin/Chemokin-Genexpression (TNFα, IL13, CSF2) 
aufweisen im Vergleich zu PEP+/+ BMMCs. Dies bedeutet, dass PEP wichtig 
für die Zytokin/Chemokin-Synthese in Mastzellen ist. Des Weiteren war die 
GC-vermittelte Hemmung der Expression von COX-2, einem 
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proinflammatorischen Gen, welches die Lipidmediator-Synthese fördert, in 
PEP-/- BMMCs beeinträchtigt. Dies bedeutet, dass PEP für die GC-induzierte 
negative Regulation der Lipidmediator-Synthese nötig ist. Ähnliche Effekte 
wie sie in PEP-/- BMMCs beobachtet wurden, konnten in PEP+/+ BMMCs 
nach Behandlung mit L75NO4, einem chemischen Inhibitor, der die PEP-
Aktivität unterdrückt, beobachtet werden. Dies zeigt, dass PEP direkt an der 
Regulation der Zytokin/Chemokin- und COX-2 Expression beteiligt ist. 
Zusammengefasst: PEP ist ein positiver Regulator der Zytokin/Chemokin- 
und COX-2 Expression und ist ebenso für die negative Regulation der COX-2 
Expression durch GC nötig. 
 
 
  
 x  
ABSTRACT 
PEST-domain-enriched tyrosine phosphatase (PEP) is a cytoplasmic protein 
tyrosine phosphatase that regulates immune cell functions, including mast cell 
functions. Mast cells are the key effector cells that initiate allergic reactions in 
response to antigen. Antigen-induced activation of mast cells causes the release of 
preformed inflammatory mediators in a process termed degranulation. There is 
also the de novo synthesis and release of lipid derived mediators, and the 
synthesis and release of cytokines/chemokines. In previous studies, PEP was 
shown to be a positive regulator of mast cell degranulation, as PEP-/- bone 
marrow derived mast cells (BMMCs) showed reduced mast cell degranulation 
when compared to PEP+/+ BMMCs. However, it is not known whether PEP 
affects other mast cell functions such as lipid mediator synthesis and 
cytokine/chemokine gene expression. Also, PEP is upregulated in BMMCs by 
dexamethasone, a steroidal antiinflammatory glucocorticoid used in the 
management of allergy, but the role of PEP in the antiallergic action of 
glucocorticoids (GCs) is not established. Using BMMCs from PEP+/+ and PEP-/- 
mice in RNA-seq experiments, it was shown that  activated PEP-/- BMMCs have 
reduced cytokine/chemokine gene (TNFα, IL13, CSF2) expression compared to 
the PEP+/+ BMMCs, meaning that PEP is important for cytokine/chemokine 
synthesis in mast cells. It was also found that the ability of GCs to negatively 
regulate the expression of PTGS2/COX-2, a proinflammatory gene that promotes 
lipid mediator synthesis was inhibited in PEP-/- BMMCs, showing that PEP is 
needed for glucocorticoid-induced negative regulation of lipid mediator 
synthesis. Treatment of PEP+/+ BMMCs with L75NO4, a chemical inhibitor of 
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PEP activity mirrored the effects observed in PEP-/- BMMCs, which means that 
PEP is directly involved in the regulation of cytokine/chemokine and 
PTGS2/COX-2 expression. In summary, PEP is a positive regulator of 
cytokine/chemokine gene expression and is required for negative regulation of 
PTGS2/COX-2 expression by GCs. 
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Chapter 1  
INTRODUCTION  
1.1 GENERAL INTRODUCTION 
Mast cells are immune cells discovered more than a century ago by the 
researcher physician Paul Erlich as cells containing cytoplasmic granules that 
were stained with metachromatic dyes (Gurish and Boyce 2006; Beaven 2009; 
Shea-Donohue et al. 2010; Ghably et al. 2015). These cells release a number of 
substances/mediators in response to extracellular stimuli (Metcalfe et al. 2009; 
Urb and Sheppard 2012; Sibilano et al. 2014). Release of mediators protects the 
body against harm by invading pathogens and other substances (Theoharides 
et al. 2007; DeBruin et al. 2015), but the mediators may also exert harmful 
effects on the body and cause disease (Rao and Brown 2008; Shea-Donohue et 
al. 2010; DeBruin et al. 2015). One of the most serious mast cell related 
diseases is anaphylaxis, which is a severe and life-threatening form of allergy 
(Theoharides et al. 2007; Metcalfe et al. 2009; Kalesnikoff and Galli 2010). 
 
Currently, the most potent class of drugs for anaphylaxis are the steroidal 
antiinflammatory glucocorticoids (GCs) (Lieberman et al. ; Simons et al. 
2011), but their use is fraught with serious side effects including type 2 
diabetes, growth retardation, hypertension, osteoporosis and impaired 
wound healing (Schacke et al. 2002; Huscher et al. 2009). To deveop GCs with 
fewer side effects there is the need to understand the mechanisms of GC 
action. One of the mechanisms by which GCs are known to exhibit 
antiinflammatory effects is the upregulation of the activity of phosphatases 
with antiinflammatory functions such as dual specific phosphatase 1 (Dusp 
1) (Kassel et al. 2001; Lasa et al. 2002). Another phosphatase, pest-domain 
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enriched tyrosine phosphatase (PEP), the subject of this investigation, was 
more recently found to be upregulated by GCs in mast cells (Maier et al. 
2007). It is possible that PEP may be a target for GC action, hence its role in 
mast cell function and glucocorticoid action merits further investigations. 
 
1.2 MAST CELL BIOLOGY 
Mast cells (MCs) are immune cells that develop from bone marrow 
progenitor cells which express both CD34 (cluster of differentiation 34) and 
the stem cell factor (SCF) receptor c-KIT (CD117) (Rottem et al. 1994; Gilfillan 
et al. 2011). These progenitor cells are released into circulation, from where 
they migrate into peripheral tissues, where they mature in response to local 
factors such as cytokines found in tissues (Metcalfe et al. 1997; Okayama and 
Kawakami 2006; Dahlin and Hallgren 2015).  
The matured mast cells found in peripheral tissues exhibit considerable degree 
of heterogeneity based on their granule content and tissue of localization. 
These tissue resident mast cells can therefore be classified into two major 
phenotypes: connective tissue mast cells (CTMC) and mucosal mast cells 
(MMC) (Miller and Pemberton 2002; Gurish and Boyce 2006; Jensen et al. 
2006). CTMC reside mainly in the skin, peritoneum and intestinal tract sub-
mucosa and characteristically express mast cell proteases (mMCP) mMCP4, 
mMCP5, and mMCP6, while MMC located mainly in the lung and 
gastrointestinal tract epithelia express mMCP1 and mMCP2 (Miller and 
Pemberton 2002; Gurish and Boyce 2006; Jensen et al. 2006). 
The growth and survival of mast cells is mainly dependent on SCF (stem cell 
factor/c-Kit ligand) (Iemura et al. 1994; Orinska et al. 2010), but other growth 
factors such as the cytokine interleukin-3 (IL-3) are also important for mast cell 
differentiation and survival (Razin et al. 1984; Westerberg et al. 2015).  
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Currently in vitro mouse models are the main stay for mast cell research 
(Reber and Frossard 2014). Mouse mast cells generated for in vitro studies are 
mostly derived from bone marrow stem cells cultivated in growth medium 
containing SCF and IL-3. When matured, the bone marrow derived mast cells 
(BMMCs) release inflammatory mediators upon activation with various 
stimuli (Radinger et al. 2015). 
 
1.3 MAST CELL ACTIVATION 
Mast cells are activated by extracellular stimuli via cell surface receptors 
(Reber and Frossard 2014). Key mast cell receptors whose activation contribute 
to health and disease include the high-affinity immunoglobulin E (IgE) 
receptor (FcRI) (binds antigens) , the c-Kit receptor (binds stem cell factor) 
and the toll-like receptors (TLRs) (binds bacterial and viral products) 
(Supajatura et al. 2001; Reber et al. 2006; Galli and Tsai 2012). They also express 
receptors that respond to venom peptides (Akahoshi et al. 2011) and receptors 
that are activated by complement proteins (Schafer et al. 2013). However, the 
FcRI which binds antigen to mediate allergic response, is the most well 
studied signalling pathway in mast cells (Reber et al. 2014). 
 
1.3.1 FcRI SIGNALLING 
FcεRI is a multichain immune recognition receptor (MMIR) that comprises of 
an α subunit, membrane spanning β subunit, and two disulﬁde-bonded γ 
subunits (αβ2). The α subunit binds IgE, while the β and  subunits are 
involved in signal transduction (Metcalfe et al. 1997; Garman et al. 1998). Prio 
to FceRI activation, the receptor forms an IgE-FcεRI complex with circulating 
IgE. Crosslinking of multiple IgE-FcεRI complex occurs after an 
antigen/allergen binds to the IgE of the complex, leading to mast cell 
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activation (Blank 2011; Sibilano et al. 2014). Mechanistically, receptor cross-
linking induces phosphorylation of receptor activation units called 
immunoreceptor tyrosine-based activation motifs (ITAM) on the β and γ 
subunits, by tyrosine kinases (notably LYN, FYN, SYK) (Gilfillan and Tkaczyk 
2006; Rivera and Gilfillan 2006). This leads to the activation of several adaptor 
molecules that form molecular scaffolds which organize the downstream 
signalling events into larger signalling complexes (Gilfillan and Tkaczyk 2006; 
Rivera and Gilfillan 2006) (Figure 1.1). These downstream signalling 
complexes are broadly classified into ‘principal/primary’ and 
‘complementary/amplification’ cascades (Gilfillan and Tkaczyk 2006). 
 
1.3.1.1   The ‘Principal/Primary’ Cascade 
Following cross-linking of FcεRI, the FcεRI proximal kinase LYN becomes auto 
phosphorylated (Figure 1.1). LYN in turn phosphorylates the ITAMs on the β 
and γ subunits of the receptor. The phosphorylated ITAMs then recruit and 
activate SYK (spleen tyrosine kinase) (Kihara and Siraganian 1994). SYK 
activates key transmembrane adaptor molecules LAT 1/2 (linker for activation 
of T cells 1/2), leading to the activation of other adaptor molecules that form 
part of the LAT molecular scaffold such as GRB2 (growth-factor receptor-
bound protein 2), GADS (GRB2-related adaptor protein), SLP76 (SH2-domain-
containing leukocyte protein of 76 kDa), including the exchange factors VAV 
and SOS (son of sevenless homologue) (Turner and Kinet 1999; Rivera and 
Gilfillan 2006). There is also activation of the kinase BTK (Bruton`s tyrosine 
kinase) whose interaction with the LAT molecular scaffold and the signalling 
enzyme PLCγ, results in the activation of PLCγ. Activated PLCγ hydrolyses 
plasma membrane associated lipid, PIP2 phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) to IP3 (inositol -1, 4, 5 —trisphosphate) and DAG 
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(diacylglycerol). IP3 acts on its receptors on the ER (endoplasmic reticulum) to 
activate Ca2+ release from intracellular stores in the ER. This leads to the 
activation of the calcium sensor STIM1 (stromal interaction molecule 1) on the 
ER membrane. STIM1 interacts with plasma membrane Ca2+ channel proteins 
to trigger Ca2+ influx through the plasma membrane into the cytoplasm 
(Gilfillan and Tkaczyk 2006; Kraft and Kinet 2007). On the other hand, DAG 
activates the signalling enzyme PKC (protein kinase C). Ca2+ and PKC induce 
mast cell degranulation (Gilfillan and Tkaczyk 2006; Kraft and Kinet 2007; 
Metcalfe et al. 2009). Elevation of cytosolic Ca2+ levels contributes to the 
activation of transcription factors such as NFAT (Nuclear factor of activated T-
cells). Alternatively, VAV and SOS activate the GTPase RAS leading to the 
activation of the mitogen activated protein kinase (MAPK) pathway through 
successive downstream phosphorylation of MAPKKK (MAPKK kinases), 
MAPKK (MAPK kinases) and the MAPKs (MAP Kinses) ERK1/2 
(extracellular signal—regulated kinase 1/2), p38 and JNK (Jun amino-terminal 
kinase) (Gilfillan and Tkaczyk 2006; Kraft and Kinet 2007). The MAPKs 
activate transcription factors belonging to the AP1 (Activator protein 1), NFB 
(Nuclear factor B) and NFAT families, to regulate gene expression (Gilfillan 
and Tkaczyk 2006; Kraft and Kinet 2007). Changes in signalling events in the 
‘principal cascade’ induces the most profound effects on mast cell effector 
functions such as degranulation, lipid mediator synthesis and release and 
cytokine/chemokine production (Gilfillan and Tkaczyk 2006; Kraft and Kinet 
2007). 
 
1.3.1.2   The ‘Complementary/Amplification’ Cascade 
The complementary pathway involves the regulation of mast cell signalling 
via the interaction of the kinases SYK and FYN with adaptor molecule 
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complex that involves GAB2 (growth-factor receptor-bound protein 2 (GRB2)-
associated binding protein 2) and the kinase PI3K (phosphatidylinositol 3-
kinase), organized by the transmembrane adaptor molecule LAT2 (Figure 1.1). 
Activated PI3K phosphorylates plasma membrane associated 
phosphoinositide PIP2 to PIP3 (phosphatidylinositol 3,4,5-triphosphate) 
resulting in increased cytosolic Ca2+ mobilisation through BTK-dependent 
phosphorylation  of  PLCγ . Alternatively, PI3K can also increase Ca2+ 
mobilisation via recruitment of PDK1 (phosphoinositide dependent protein 
kinase 1), which activates PLD (phospholipase D). PLD activates SPHK 
(sphingosine kinase) to induce the break down of sphingosine to form S1P 
(sphingosine 1-phosphate), which triggers Ca2+ entry through the plasma 
membrane (Gilfillan and Tkaczyk 2006; Kraft and Kinet 2007). Also, PI3K 
activation leads to PDK1 activation of the protein kinase AKT. AKT 
participates in the regulation of various transcription factors (Gilfillan and 
Tkaczyk 2006; Kraft and Kinet 2007). 
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Figure 1.1 Model of FcεRI signalling. In the primary/principal cascade, activated LYN phosphorylates 
immunoreceptor tyrosine-based activation motifs (ITAMs) in the β- and γ-chains of the high-affinity Fc 
receptor for IgE (FcεRI), which results in association of SYK with the γ-chains and subsequent SYK 
activation. SYK phosphorylates LAT1/2 (linker for activation of T cells 1/2), which recruits GADS (growth-
factor-receptor-bound protein 2 (GRB2)-related adaptor protein), SLP76 (SH2-domain-containing leukocyte 
protein of 76 kDa), VAV and PLCγ (phospholipase Cγ) to form a LAT scaffold complex. PLCγ is activated 
through the LAT complex via BTK (Bruton’s tyrosine kinase) mediated phosphorylation of PLCγ. Activated 
PLCγ produces IP3 (inositol-1,4,5-trisphosphate) and DAG (diacylglycerol) from PIP2 phosphatidylinositol-
4,5-bisphosphate (PtdIns(4,5)P2). IP3 activates its receptor (IP3R) on the ER (endoplasmic reticulum) to 
induce Ca2+ (calcium) release from the ER stores. ER Ca2+ stores depletion leads to STIM1 (stromal 
interaction molecule 1)-guided opening of plasma membrane Ca2+ channels, which causes the influx of 
extracellular Ca2+. DAG activates PKC (protein kinase C) which collectively with Ca2+ mobilization activate 
degranulation. In the complementary/amplification cascade, FYN and SYK activation induce a signalling 
complex with GAB2 (growth-factor receptor-bound protein 2 (GRB2)-associated binding protein 2) and the 
kinase PI3K (phosphatidylinositol 3-kinase), organized by the transmembrane adaptor molecule LAT2. PI3K 
activation leads to Ca2+ mobilisation via BTK-dependent phosphorylation of PLCγ and membrane 
recruitment of PDK1 (3-phosphoinositide-dependent protein kinase 1) to activate PLD (phospholipase D) 
which activates SPHK (sphingosine kinase) to induce the break down of sphingosine to form S1P 
(sphingosine 1-phosphate) leading to Ca2+ entry through the plasma membrane. PI3K activation also leads to 
PDK1 mediated activation of the protein kinase AKT. GRB2 and SOS (son-of-sevenless homologue) are 
associated with both the primary and complementary cascades and lead to RAS activation, which then leads 
to the activation of MAPK (mitogen-activated protein kinase) cascade that contributes to 
cytokine/chemokine and eicosanoid production. Modified from Kraft and Kinet 2007. 
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1.4 MAST CELL MEDIATORS 
Mast cells release a repertoire of mediators when activated (Radinger et al. 
2015). The release of mediators is generally a consequence of FcRI activation 
by antigen/allergen, although other stimuli such as viral and bacteria particles 
can also contribute to mast cell mediator release (Gilfillan and Tkaczyk 2006). 
 
The mediators released by activated mast cells belong to a wide range of 
chemical and biological classes, but they can be classified as (1) 
preformed/granule mediators which are stored in cytoplasmic granules, the 
contents of which are released by the process of exocytosis; (2) lipid-derived 
mediators such as the eicosanoids (prostaglandins, prostacyclin, leukotrienes, 
thromboxanes) which are synthesized de novo and (3) cytokines/chemokines 
and growth factors generated from induction of gene expression (Da Silva et 
al. 2006; Kalesnikoff and Galli 2010; Reber and Frossard 2014). 
 
1.4.1 PREFORMED/GRANULE MEDIATORS 
Mast cell preformed mediators are released within seconds to minutes after 
cell surface receptor activation (Metcalfe et al. 2009; Urb and Sheppard 2012). 
These mediators include proteases (tryptase, chymase) and biogenic amines 
(histamine and serotonin), lysosomal enzymes (β-hexosaminidase), and some 
cytokines such as tmour necrosis factor alpha (TNFα)(Pejler et al. 2007; Kunder 
et al. 2009; Wernersson and Pejler 2014). They are stored in granular structures 
in the cytoplasm and released in a process termed degranulation (Nishida et 
al. 2005; Yamasaki and Saito 2005). These mediators generally induce 
vasodilation leading to hypotension, and hypothermia that is associated with 
severe allergic reactions (Kemp and Lockey 2002) such as anaphylaxis. 
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1.4.2 LIPID-DERIVED MEDIATORS 
In addition to preformed mediators, mast cell activation induces de novo 
synthesis and release of lipid-derived mediators (Firestein et al. 2015; Radinger 
et al. 2015). The key mast cell lipid derived mediators, PGD2 (prostaglandin 
D2), leukotrienes LTC4 (leukotrienes C4) and LTB4 are products derived from 
arachidonic acid (AA) metabolism (Firestein et al. 2015; Radinger et al. 2015). 
Upon activation of mast cells, arachidonic acid (AA) is released from 
membrane phospholipids by the catalytic activities of PLA2 (phospholipase 
A2)(Clark et al. 1991; Boyce 2007). The AA released is metabolised by COX-1 
and COX-2 (cyclooxygenases 1 and 2) to form an unstable intermediate, PGG2 
(prostaglandin G2), which is rapidly converted to PGH2 (prostaglandin H2) 
(Figure 1.2). PGH2 is converted to PGD2 by the terminal isomerase H-PGDS 
(haematopoietic prostaglandin D2 synthase), (Figure 1.2). PGD2 induces Th2 
lymphocytes, eosinophils and neutrophil recruitment and contributes to 
bronchoconstriction and vascular leak associated with allergic conditions such 
as anaphylaxis (da Silva et al. 2014; Firestein et al. 2015) 
COX-1/2 are the rate liming enzymes for PGD2 synthesis. Whereas COX-1 is 
constituvely expressed to maintain normal physiological levels of eicosanoids, 
COX-2 expression is induced in response to inflammatory stimuli. COX-2 is 
thus responsible for pathological regulation of PGD2 synthesis. Consequently, 
inhibition of COX-2 activity is a key mechanism by which the most 
commonly used antiinflammatory drugs, the non-steroidal antiinflammatory 
drugs (NSAIDs) such as aspirin and steroidal antiinflammatory 
glucocorticoids such as dexamethasone exhibit their therapeutic effects 
(Goulding 2004; Hayashi et al. 2004; Fendrick and Greenberg 2009; Candido 
et al. 2017). 
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Correspondingly, leukotriene production in mast cells requires the initial 
conversion of AA to LTA4 by 5-lipoxygenase (5-LO). LTA4 is then converted to 
LTB4 by LTA4 hydrolase (LTA4H) or to LTC4 by LTC4 synthase (LTC4S) 
(Figure 1.2). These leukotrienes trigger recruitment of eosinophils, neutrophils 
and T lymphocytes. They also induce increased vascular permeability and 
bronchoconstriction that occur in allergic diseases (Kim et al. 2006; Barrett et 
al. 2011; da Silva et al. 2014). Together, the lipid mediators contribute to acute 
inflammatory resonse associated with mast cell activation (Firestein et al. 
2015). 
 
 
 
 
Figure 1.2 COX-2 (Cyclooxygenase-2) pathway for prostaglandin D2 and leukotriene synthesis: COX-
1 and COX-2 (cyclooxygenases 1 and 2) catalyses AA (arachidonic acid) released from membrane 
phospholipids by PLA2 (phospholipase A2) activity to an unstable intermediate, PGG2 (prostaglandin G2), 
which is rapidly converted to PGH2 (prostaglandin H2). PGH2 is converted to PGD2 by the terminal 
isomerase H-PGDS (hematopoietic prostaglandin D2 synthase). 5-LO (5-lipoxygenase) converts AA to 
LTA4 (leuckotriene A4) which is then converted to LTB4 by LTA4H (LTA4 hydrolase) or to LTC4 by 
LTC4S (LTC4 synthase) Evans et al. (1985). 
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1.4.3 Cytokines/Chemokines 
Mast cell activation induces the synthesis and release mediators that derive 
from induction of gene expression. Pathologically important classes of such 
mediators are proinflammatory cytokines/chemokines such as TNFα, IL-1, 
and IL-6; IL-4, IL-5, IL-10, IL-13; CCL2 and CSF2 (Metcalfe et al. 1997; Gilfillan 
and Tkaczyk 2006; Kraft and Kinet 2007). Some of these cytokines/chemokines 
notably TNFα, may be prestored and released rapidly after mast cell activation 
(Firestein et al. 2015). These cytokines/chemokines activate other immune cells 
such as neutrophils, T cells and B cells to release their own mediators, which 
results in the amplification and perpetuation of the inflammatory response 
(Kalesnikoff and Galli 2010; Reber and Frossard 2014). 
 
1.5 PROTEIN TYROSINE PHOSPHATASES 
The status of mast cell activation at any point in time is a balance between 
activation and inhibitory pathways (Gilfillan et al. 2011; Sibilano et al. 2014). 
The reason being that, inappropriate activation of mast cells can lead to life 
threatening disease conditions such as anaphylaxis (Peavy and Metcalfe 
2008; Gilfillan et al. 2011).  
Normaly, mast cell FcRI activation is promoted by protein tyrosine kinases 
(PTKs) (Gilfillan and Tkaczyk 2006; Rivera and Gilfillan 2006), while 
inhibition is mediated by various phosphatases including protein tyrosine 
phosphatases (PTPs) (Kalesnikoff and Galli 2010). PEST-domain-enriched 
tyrosine phosphatase (PEP), is one of such PTPs, more recently suggested to be 
involved in the regulation of mast cell functions (Obiri et al. 2012).  
 
1.5.1 PEP 
PEST-domain-enriched tyrosine phosphatase (PEP in mouse) known as Lyp in 
humans, is a cytoplasmic PTP. Structually, it is an 802 amino residue protein 
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with a 200 amino acid C-terminus domain containing four proline rich 
sequences for protein-protein interactions (Matthews et al. 1992; Cloutier and 
Veillette 1996) and a PEST (proline-glutamic acid-serine-threonine) sequence 
that may signal the protein for degradation (Matthews et al. 1992). The C-
terminus shares about 60% homology, while the N-terminus shares 90% 
homology with Lyp (Cohen et al. 1999). The N-terminus contains the 
phosphatase domain of about 300 amino acid residues (Cohen et al. 1999).  
PEP is involved in various chronic diseases (Bottini et al. 2004; Bottini and 
Peterson 2014). Disease associated studies showed that alterations in the Lyp 
gene is a risk factor for human diseases including inflammatory conditions 
such as rheumatoid arthritis (Vang et al. 2008), showing that PEP is involved 
in immune regulation. In their studies to understand the role of PEP in 
immune cell functions, Hasegawa and colleagues used murine gene knock-out 
models to show that PEP deficient mice are viable and fertile. They established 
that although young PEP -/- mice (4-6 weeks) did not show morphological 
differences compared to WT, older mice (above 6 months ) had larger lymph 
nodes and spleen (Hasegawa et al. 2004). These older mice had higher 
effector/memory T cell populations and higher number of germinal centres in 
the spleen and Peyer’s patches (Hasegawa et al. 2004). Furthermore, T cells 
from PEP-/- mice exhibited increased proliferation, increased 
cytokine/chemokine production, and elevated intracellular Ca2+ (Hasegawa et 
al. 2004). Also, studies using Jurkat T-cells in which PEP was overexpressed in 
a luciferase reporter system, showed that induced expression of PEP reduced 
the activation of proinflammatory transcription factors (NFAT and AP1). It 
was therefore concluded that PEP is a negative regulator of T cell effector 
functions (Gjorloff-Wingren et al. 1999). Subsequently, it was shown that PEP 
interacts synergistically with Csk (C-terminal Src kinase) to down regulate the 
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phosphorylation of the Src kinases Lck (Lyn in mast cells) and Zap-70 (Syk in 
mast cells) (Cloutier and Veillette 1999). This inhibition of Lck and Zap-70 by 
PEP were found to be associated with its phosphatase activity in a substrate 
trapping experiment using catalytically inactive mutants of PEP (Cloutier and 
Veillette 1999; Gjorloff-Wingren et al. 1999), suggesting that PEP phosphatase 
activity negatively regulates T cell functions. PEP was shown to be 
upregulated by glucocorticoids (GCs) in mast cells (Maier et al. 2007). Initial 
investigations to understand the role of PEP in mast cells did show that PEP 
promotes anaphylaxis in mice, and that PEP is needed for GC-mediated 
inhibition of anaphylaxis (Obiri et al. 2012). However, the mechanisms by 
which PEP regulates mast cell functions and its contribution to the 
antiinflammatory/antiallergic action of GCs is currently not clear and needs 
further investigation. 
 
1.6 GLUCOCORTICOIDS 
Glucocorticoids (GCs) are a class of steroid hormones produced in the adrenal 
cortex from cholesterol, by the hypothalamic—pituitary—adrenal (HPA) axis in 
response to psychogenic, physical and immune challenges (Cain and 
Cidlowski 2015; Ramamoorthy and Cidlowski 2016; Cain and Cidlowski 2017). 
The name glucocorticoids derive from the ability of these adrenal steroids to 
promote the conversion of proteins and lipids into glucose during stress-
induced activation of the HPA axis (Smith and Vale 2006; Gross and 
Cidlowski 2008). They were discovered to exert beneficial effects in 
inflammatory conditions such as rheumatoid arthritis, for which Kendall, 
Reichstein and Hench received the Nobel Prize in Physiology and Medicine in 
1950 (Burns ; Benedek 2011). Subsequently, various synthetic GCs have been 
used in the treatment of autoimmune diseases, inflammatory disorders and 
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cancer, making GCs one of the most widely prescribed classes of drugs 
(Barnes 2006; Gross and Cidlowski 2008; Cain and Cidlowski 2017). However, 
their  involvement in glucose, fat and protein metabolism causes serious side 
effects such as type 2 diabetes, growth retardation, impaired wound healing, 
osteoporosis and hypertension (Barnes 2006; Cain and Cidlowski 2015, 2017). 
Additionally, a small number of patients do not respond at all or develop 
reduced response to GCs with chronic use (Ito et al. 2006; Caratti et al. 2015). 
Consequently, the need to develop potent GCs with less side effects has 
generated continuous research into the mechanism of GC action, but for 
several decades the molecular mechanism of GC action is not fully 
understood, for a number of reasons. For example, the mechanisms of 
glucocorticoid action are manifold, as they regulate up to 20% of the 
transcriptome according to some studies (Galon et al. 2002; Cain and 
Cidlowski 2017). Also, glucocorticoid receptors are expressed by nearly all 
nucleated cells with some cell-type specific differences in GC functions 
(Coutinho and Chapman 2011). Thus, many aspects of GC actions remain 
uncovered. To develop potent GCs with minimal side effects, it is important to 
have full understanding of the mechanism of GC action. 
 
1.7 MECHANISM OF GLUCOCORTICOID ACTION 
GCs diffuse across lipid membranes into cellular compartments such as the 
cytoplasm where they interact with the glucocorticoid receptor (GR), which 
belongs to the superfamily of nuclear receptors of transcription factors 
(Hollenberg et al. 1985). GCs induces changes in cellular functions that is 
broadly classified as either genomic or non-genomic (Gross and Cidlowski 
2008; Stahn and Buttgereit 2008; Mitre-Aguilar et al. 2015). The genomic 
mechanisms involve the transport of a cytoplasmic glucococrticoid receptor 
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(GR) into the nucleus upon ligand (GC) binding, resulting in the activation or 
repression of gene transcription (Cato and Wade 1996; Cain and Cidlowski 
2017). On the other hand, the non-genomic mechanisms involves rapid 
changes that occur through physiochemical interactions of GC or ligand -
activated GR with cellular components independent of GR nuclear transport 
(Gross and Cidlowski 2008; Stahn and Buttgereit 2008; Buttgereit et al. 2011; 
Cain and Cidlowski 2017). Although both genomic and non-genomic 
mechanisms modulate cell functions, studies to understand the 
antiinflammatory action of GCs have focused mainly on the GR mediated 
genomic effects, since they are the main mode by which GCs exhibit their 
antiinflammatory effects (Rhen and Cidlowski 2005; Barnes 2006; Desmet and 
De Bosscher 2017). In the nucleus, glucocorticoid activated GR, represses or 
activates target gene expression. 
 
1.7.1 REPRESSION OF GENE EXPRESSION 
Glucocorticoids repress gene expression via multiple mechanisms, generally 
termed transrepression. Once inside the nucleus, the GR as a homodimer can 
bind directly to DNA sequencies called negative glucocorticoid response 
elements (nGRE), to inhibit target gene expression (Moutsatsou et al. 2012; 
Cain and Cidlowski 2017). This binding of GR as a homodimer to the nGREs 
denies assess to target gene promoter for other factors involved in 
transcription, leading to the repression of gene transcription (Subramaniam et 
al. 1998; Zhou and Cidlowski 2005; Zen et al. 2011). Example of transcriptional 
repression through nGRE occurs when the GR binds to nGREs of osteocalcin, a 
gene involved in bone formation. This prevents binding of transcription 
factors belonging to the basal transcriptional machinery (BTM), whose binding 
site overlap with the nGRE of osteocalcin (Morrison and Eisman 1993; Meyer 
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et al. 1997). This inhibition of osteocalcin gene expression leads to impairement 
of bone formation as observed in osteoporosis, which is a major adverse effect 
of GC use (Moutsatsou et al. 2012). Likewise, the GC-activated GR in the 
nucleus also interacts with nGREs to exhibit antiinflammatory effects as 
observed for TSLP (Thymic stromal Lymphopoietin), a cytokine known to 
induce atopic dermatitis (Surjit et al. 2011).  
Alternatively, the GR as a monomer can interfere with the function of DNA 
bound transcription factors (TFs) via protein-protein interactions termed 
“tethering”, to repress gene expression (Cato and Wade 1996; Ratman et al. 
2013). This tethering of GR to other TFs alters the assembly of coactivator 
complexes that are required for gene expression, leading to the repression of 
target gene expression (Glass and Saijo, 2010; Luecke and Yamamoto, 2005; 
Ogawa et al., 2005; Rogatsky et al., 2002; Schule et al., 1990). By tethering to 
immune-regulating transcription factors such as AP-1 (activator protein 1), 
NF-B (nuclear factor 'kappa B), NF-AT (nuclear factor of activated T cells), 
CREB (cyclic AMP-responsive element-binding protein), STAT3 (Signal 
transducer and activator of transcription 3) STAT6, IRF3 (Interferon 
Regulatory Factor 3), GATA- 3 (GATA binding protein 3) and t-Bet (T-Box 
transcription Factor TBX21), GR represses the expression of a number of 
cytokines/chemokines (TNFα, GM-CSF, IL-1b, IL-2, IL-3, IL-6, IL-8, IL-11, 
IL13) (Beck et al., 2009; De Bosscher et al., 2003; Langlais et al., 2012; Liberman 
et al., 2007, 2009a, 2009b; Reily et al., 2006) and COX-2 in immune cells 
(Revollo and Cidlowski 2009; Cain and Cidlowski 2017). 
 
1.7.2 ACTIVATION OF GENE TRANSCRIPTION 
The genomic action of the GR also involves the activation of gene expression 
via mechanisms collectively termed transactivation (Smoak and Cidlowski 
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2004). Classically, the GR binds as a homodimer to DNA sequences called 
positive glucocorticoid response elements (+GREs) to activate the expression 
of target genes (Beato 1989; Beato et al. 1996). This process involves the 
recruitment of several coactivators with histone acetylase (HAT) activity, such 
as CBP/p300(CREB-binding protein/p300), and SRC-1 (Smoak and Cidlowski 
2004; Tronche et al. 2004; Revollo and Cidlowski 2009; King et al. 2012), and 
also non-HAT containing cofactors including SWI/SNF and pCIF to the GR-
DNA complex (De Bosscher et al., 2003). Typical examples of genes controlled 
via this mechanism, include genes involved in glucose and fat metabolism, 
such as glucose-6-phosphatase and PEPCK (phosphoenolpyruvate 
carboxykinase), whose expression contributes to the impaired glucocse and fat 
metablosim associated with GC action (van Raalte et al. 2009; Ratman et al. 
2013). Similarly, genes with antiinflammatory effects such as lipocortin, 
mitogen-activated protein kinase phosphatase-1/dual specificity 
phosphatase 1 (MKP-1/Dusp1) (Lu and Cidlowski 2006; Bhattacharyya et al. 
2007; Moutsatsou et al. 2012) and GILZ (glucocorticoid-induced lucine zipper) 
(Clark, 2007; Newton and Holden, 2007). 
Also, the GR may induce target gene expression via interaction with DNA-
bound TFs through protein-protein interaction without binding to DNA 
(Beato 1989; Beato et al. 1996; Moutsatsou et al. 2012). A typical example for 
such mechanism is the transactivation of the antiinflammatory cytokine IL-
10, which occurs through protein-protein interaction between GR and the 
transcription factor STAT3 (Unterberger et al. 2008). 
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1.8 AIM 
PEP is a protein tyrosine phosphatase that regulates immune cell function. 
PEP gene knock-out studies have shown that PEP promotes mast cell 
mediated anaphylaxis. In mast cells, PEP expression is upregulated by the 
antiinflammatory glucocorticoid (GC) dexamethasone. However, the role of 
PEP in mast cell function and its contribution to GC action is not clear. 
Therefore, this project aims to study the role of PEP in antigen-mediated mast 
cell response, and to investigate whether the antiinflammatory/antiallergic 
action of GCs in mast cells is mediated by PEP. 
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Chapter 2  
MATERIALS AND METHODS 
2.1 MATERIALS 
 
2.1.1 CHEMICALS 
General Laboratory Chemicals  Source 
5 Green GoTaq reaction buffer  Promega, Mannheim 
β‐Mercaptoethanol    Carl Roth GmbH & Co., Karlsruhe 
Acrylamide/Bis‐Acrylamide  Carl Roth GmbH & Co., Karlsruhe 
Ammonium persulfate (APS)  Carl Roth GmbH & Co., Karlsruhe 
Ammonium Chloride (NH4Cl)  Carl Roth GmbH & Co., Karlsruhe 
Bromophenol blue  BioRad., Heidelberg 
Bovine Serum Albumin (Powder)   GE Healthcare Life Science USA 
Calcium chloride (CaCl2)  Carl Roth GmbH & Co., Karlsruhe 
Dimethyl sulfoxide (DMSO)   Carl Roth GmbH & Co., Karlsruhe 
Dithiothreitol (DTT)   Carl Roth GmbH & Co., Karlsruhe 
ECL (Western Blotting Substrate)   BioRad, Heidelberg 
Ethanol   Carl Roth GmbH & Co., Karlsruhe 
Ethidium bromide  Carl Roth GmbH & Co., Karlsruhe 
Glucose   Carl Roth GmbH & Co., Karlsruhe 
Glycerol     Carl Roth GmbH & Co., Karlsruhe 
Glycine  Carl Roth GmbH & Co., Karlsruhe 
GoTaq polymerase   Promega, Mannheim 
HEPES   Carl Roth GmbH & Co., Karlsruhe 
Isopropanol      Carl Roth GmbH & Co., Karlsruhe 
Magnesium chloride   Carl Roth GmbH & Co., Karlsruhe 
Magnesium sulphate   Carl Roth GmbH & Co., Karlsruhe 
Methanol   Carl Roth GmbH & Co., Karlsruhe 
Milk powder (dry)  Saliter, Obergünzburg 
Moloney Murine Leukemia Virus Reverse Transcriptase, 
RNase (H‐) Point Mutant (M‐MLV RT [H–])  Promega , Mannheim 
M‐MLV RT 5 buffer  Promega, Mannheim 
PageRuler Prestained  Protein Ladder  Thermo Fischer Scientific, USA 
PeqGOLD Universal Agarose  PeqLab, Erlangen 
Potassium chloride (KCl)  Carl Roth GmbH & Co., Karlsruhe 
Potassium hydrogen carbonate (KHCO3)  Carl Roth GmbH & Co., Karlsruhe 
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General Laboratory Chemicals (Continuation)  Source 
Potassium phosphate dibasic (K2HPO4)  Carl Roth GmbH & Co., Karlsruhe 
Protassium phosphate monobasic (KH2PO4)  Carl Roth GmbH & Co., Karlsruhe 
Proteinase K  Carl Roth GmbH & Co., Karlsruhe 
Sodium acetate   Carl Roth GmbH & Co., Karlsruhe 
Sodium chloride  Carl Roth GmbH & Co., Karlsruhe 
Sodium dodecylsulphate (SDS)  Carl Roth GmbH & Co., Karlsruhe 
Sodium hydroxide  Carl Roth GmbH & Co., Karlsruhe 
Tris‐base  Carl Roth GmbH & Co., Karlsruhe 
Tris hydrochloride (Tris‐HCl)  Carl Roth GmbH & Co., Karlsruhe 
Tetramethylethylenediamine(TEMED)  Carl Roth GmbH & Co., Karlsruhe 
Tween‐20  Carl Roth GmbH & Co., Karlsruhe 
 
2.1.2 PEP INHIBITOR 
Chemical  Source    Use 
L75N04 
Kind gift from Dr. Zhong-Yin 
Zhang, Indiana, USA, (He et al 
2013)
5 M 
 
2.1.3 CELL CULTURE MATERIALS 
Chemicals  Source 
1 Dulbeccos’s Phosphate Buffered Saline (PBS)   GIBCO, Thermo Fisher Scientific, USA 
70 m falcon cell strainer  Corning, Kaiserslautern 
β‐ mercaptoethanol (Cell culture grade)  Sigma‐Aldrich Chemie, Steinheim 
Cell culture Dishes, flasks and multiwell plates  Greiner Bio‐one GmbH, Frickenhausen 
Dexamethasone  Sigma‐Aldrich Chemie, Steinheim 
DNP‐BSA (Albumin from Bovine Serum (BSA), 2,4‐
Dinitrophenylated) 
Molecular Probes, Thermo Fisher 
Scientific, USA 
FBS (South American Origin)  GIBCO, Thermo Fisher Scientific, USA 
Iscove's Modified Dulbecco's Medium (IMDM)  GIBCO, Thermo Fisher Scientific, USA 
L‐glutamine  GIBCO, Thermo Fisher Scientific, USA 
Murine monoclonal anti‐ditrophenyl IgE (clone SPE‐7)  Sigma‐Aldrich Chemie, Steinheim 
Murine stem cell factor (c‐Kit ligand) 
Kind gift from Stassen, M (Stassen et al.
2006) 
Recombinant Murine Interleukin 3 (IL‐3)   PreproTech, Rocky Hill, NJ 
Sodium Pyruvate  GIBCO, Thermo Fisher Scientific, USA 
Penicillin/Streptomycin 10000 U/ml  GIBCO, Thermo Fisher Scientific, USA 
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2.1.4 ANTIBODIES 
Primary Antibodies  Source    Use 
Anti‐PEP   Kind gift from A. Chan (Hasegawa et al 2004). 
1 : 2000 in 5% milk (in 
1 TBST), 4°C O/N 
P38 (C‐20) sc‐535 rabbit 
polyclonal IgG, 200 g/ml  Santa Cruz, Heidelberg 
1 : 1000 in 5% milk (in 
1 TBST), 4°C O/N 
 
 
Secondary Antibodies  Source    Use 
Goat anti‐mouse IgG HRP 
conjugate  Advansta, USA 
1 : 10000 in 5% milk
(in 1 TBST), 45 min 
at RT 
Goat anti‐rabbit IgG HRP 
conjugate  Advansta, USA   
1 : 10000 in 5% milk
(in 1 TBST), 45 min 
at RT 
 
 
2.1.5 OLIGONUCLEOTIDES 
PEP genelocus‐specific primers  Sequence 
KH‐1  5’‐AATGCCCGCTTGATGAGCAGAGGTCTG‐3’ 
KH‐2  5’‐GGCTTCTTTCAGTAGTTGCTGCAGAAT‐3’ 
KH‐4  5’‐TGCTAAAGCGCATGCTCCAGACTGC‐3’ 
 
 
Primers for qRT‐PCR  Sequence 
CSF2  Forward 5'‐TCGTCTCTAACGAGTTCTCCTT‐3'Reverse  5'‐CGTAGACCCTGCTCGAATATCT‐3' 
GAPDH  Forward 5'‐CTGAGGACCAGGTTGTCTCC‐3'Reverse  5'‐TGTGAGGGAGATGCTCAGTG‐3' 
IL13  Forward 5'‐TGGCTCTTGCTTGCCTTGGT‐3'Reverse  5'‐TTTTGGTATCGGGGAGGCTGG‐3' 
PTGDS/L‐PGDS  Forward 5'‐GCTCCTTCTGCCCAGTTTTCCT‐3'Reverse  5'‐GGAGGACCAAACCCATCCAC‐3' 
PTGS2/COX‐2  Forward 5'‐TGAGCAACTATTCCAAACCAGC‐3'Reverse  5'‐GCACGTAGTCTTCGATCACTATC‐3' 
Ribosomal protein, large, P0 (Rplp0)
 
Forward  5'‐GGACCCGAGAAGACCTCCTT‐3'
Reverse  5'‐GCACATCACTCAGAATTTCA‐3' 
TNFα  Forward 5'‐GATCGGTCCCCAAAGAAGGGATG‐3'Reverse  5'‐TGATCTGAGTGTGAGGGTCTCG‐3' 
 
 
2.1.6 CELL TYPES AND CULTURE MEDIUM 
Cell type  Description    Medium 
BMMCs 
Bone marrow derived mast 
cells (primary murine mast 
cells) 
 
IMDM + 10% FBS, 2 mM L‐glutamine, 1 
mM Pyruvate, 1% Penicillin/Streptomycin, 
100 ng/ml SCF, 10 ng/ml IL3, 50 M  
β‐mercaptoethanol 
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2.1.7 ANIMALS 
The PEP+/+ and PEP-/- C57BL/6 mice used in this work were generated by 
successive crossing of PEP+/- C57BL/6 germline mice (obtained from 
Genentech Inc., South San Franciso) with wild-type C57BL/6 mice, over 10 
generations, in the Animal Facility of ITG, KIT.  
The C57BL/6 PEP+/- germline was generated by the group of Andrew Chan, 
by using homologous recombination to disrupt the endogenous PEP gene in 
embryonic stem cells (ES), to generate PEP+/- ES. The PEP+/- ES were 
injected into C57BL/6 blastocysts to yield chimeric mice that were crossed 
with wild-type C57BL/6 mice to generate the PEP+/- germline mice 
(Hasegawa et al. 2004). 
To generate PEP+/+ and PEP-/- BALB/c mice, BALB/c mice were crossed 
with PEP-/- C57BL/6 mice for 10 generations.  
 
All mice were bred in the Animal Facility of ITG (safety level S1, in specific 
pathogen free conditions and in a 12 hour Light-Dark cycle, with food and 
water available ad libitum. The breeding of mice and animal experiments were 
carried out in accordance with the German legislation guidelines for care and 
use of laboratory animals. 
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2.2 METHODS 
 
2.2.1 NUCLEIC ACID METHODS 
 
2.2.1.1  Genotyping of Mice 
 
a) Isolation of Genomic DNA from Mouse Tail Biopsies 
To determine the genotype of mice, mouse tail biopsies were lysed in 200 μl of 
tail lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM 
NaCl, 100 g/ml Proteinase K) in 1.5 ml eppendorf tubes, with shaking at 55˚C 
on a thermal block (Eppendorf Thermomixer 5436, Eppendorf-Netheler-Hinz— 
GmbH, Hamburg) for 3 h. After lysis, the lysate was centrifuged for 5 min at 
14000 rpm (Eppendorf Centrifuge 5417R, Eppendorf AG, Hamburg), to pellet 
hair and other tissue debris. The supernatant containing the DNA was 
transferred into 1.5 ml eppendorf tube containing 200 μl of isopropanol to 
precipitate the DNA. The mixture was centrifuged for 5 min at 14000 rpm and 
the supernatant discarded, leaving a pellet of DNA. The eppendorf tube was 
turned upside down on a Kleenex paper to dry the pellet. The pellet was 
further dried for 5 min on thermal block, at 37˚C. The DNA pellet was 
dissolved in 100 μl of TE buffer (10 mM Tris-HCl, 0.1 mM EDTA pH 8) with 
shaking on the thermal block for 30 min. The DNA was used immediately or 
stored at -20˚C for future use. 
 
b) PCR with PEP Genelocus-Specific Primers 
DNA (section 2.2.1.1a), 4 l each, was pipetted into two separate PCR tubes. 
Then 16 l of a master mix A, containing the PEP genelocus-specific primers 
KH-1 (forward) and KH-2 (reverse) (4 l of 5 Go Taq Reaction Buffer, 10 mM 
dNTPs, 10 pM KH-1, 10 pM KH-2, 25 l GoTaq Polymerase (5 U/l), 9.25 l 
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dH20) was added to one of the DNA templates, while 16 l of a master mix B 
containing KH1 (forward) and KH4 (reverse) (4 l of 5 Go Taq Reaction 
Buffer, 10 mM dNTPs, 10 pM KH-1, 10 pM KH-4, 25 l GoTaq Polymerase (5 
U/l), 9.25 l dH20) was added to the other DNA template.  
The PCR was carried out in a thermocycler (GeneAmp PCR System 2700, 
Applied Biosystems), using the following PCR protocol: 
 
PCR Protocol 
Step  Temperature  Time  Number of cycles 
1  95  3 min 
2  95  1 min  27 
3  55  1 min  27 
4  72  1 min  27 
5  4°C  Hold 
 
The oligonucleotides KH1 (forward) and KH2 (reverse) anneal within the 
genomic sequence of PEP gene, outside the left and right border, respectively, 
of a neo cassette (origionally inserted in the exon 1 to disrupt the PEP gene), 
while KH4 anneals within the neo cassette sequence (Hasegawa et al. 2004). 
Thus, master mix A (KH1 + KH2) will produce amplified product size of about 
550 bp, if the template DNA contained wild-type allele, and master mix B 
(KH1 + KH4) will produce a product size of about 450 bp, if the template DNA 
contained mutated allele. The amplication products were subjected to agarose 
gel electrophoresis for detection. 
 
c) Agarose Gel Electrophoresis 
Separation of DNA fragments was carried out using 2% w/v agarose gel  
The gel was prepared by heating agarose powder in 1 TAE buffer (40 mM 
Tris-base pH 7.2, 20 mM sodium acetate, 1 mM EDTA) to boiling. The boiled 
agarose solution was cooled to 60˚C and ethidium bromide (intercalating 
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agent added as a fluorescent tag) was added to a final concentration of 0.3 
g/ml. The gel solution was then poured into a horizontal electrophoresis 
chamber (Owl Seperations Systems) and a comb inserted to make wells whiles 
the gel polymerises.  
The polymerised gel was overlaid with 1 TAE buffer, and PCR samples 
loaded into wells. The electrophoresis was carried out at 120V for 45 min. 
DNA bands were thereafter visualised under UV light using a 
transilluminator fitted with Eagle Eye photo camera system (Peqlab 
Biotechnologie GmbH, Erlangen). 
 
 
2.2.1.2  RNA Analysis 
 
a) Phenol:Chlorophorm Extraction of RNA from Bone Marrow Derived Mast 
Cells (BMMCs) 
BMMCs suspension of 2-3 x 106 cells/ml in 1.5 ml eppendorf tube was 
centrifuged (Eppendorf Centrifuge 5417R, Eppendorf AG, Hamburg) at 2000 
rpm for 5 min at 4˚C to pellet the cells. The medium was discarded and the cell 
pellet lysed in 1 ml of PeqGOLD RNAPure reagent for 5 min at room 
temperature (RT). To extract RNA, 200 μl of chloroform was added, vortexed 
for 15 s and incubated on ice for 5 min. The mixture was then centrifuged at 
14000 rpm for 10 min at 4˚C, to separate RNA, DNA and proteins into phases. 
After centrifugation, 400 μl of the upper RNA containing aqueous phase was 
transferred into eppendorf tube containing 5 g glycogen (in 5 μl, as a carrier 
molecule to enhance RNA precipitation). The resulting mixture was vortexed 
and incubated at RT for 5 min. Thereafter, 400 μl of isopropanol was added, 
vortexed, and incubated on ice for 15 min to precipitate RNA. The mixture 
was centrifuged at 14000 rpm for 10 min at 4˚C to pellet the RNA. After 
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centrifugation, the supernatant was discarded. Residual isopropanol around 
the RNA pellet was washed off, twice, with 1 ml 75% ethanol (cold), by 
vortexing for 5 s and then centrifugation at 14000 rpm for 10 min at 4˚C. After 
the last wash, eppendorf tube was turned upside down on a Kleenex paper 
under fume chamber for 10 min to dry the pellet. The dried pellet was 
dissolved in 20 μl sterile RNAse-free water by incubating on heat block 
(Eppendorf Thermomixer 5436, Eppendorf-Netheler-Hinz— GmbH, Hamburg) 
at 37˚C for 10 min, and then at 56˚C for 5 min, to denature RNAses. RNA 
concentration and purity was measured using Nanodrop ND-1000 
spectrophotometer (PeqLab Biotechnologie GmbH, Germany). The samples 
were used immediately or stored at -80 for future use. 
 
b) Quantification of RNA Concentration 
The concentration of RNA was determined by measuring the optical density 
(OD) of 2 l of RNA sample at 230, 260 and 280 nm using NanoDrop ND-
1000 spectrophotometer (PeqLab Biotechnologie GmbH, Germany). A ratio of 
OD260/OD280 within 1.8-2.0 indicates a sample of acceptable purity, 
relatively free of proteins, while OD260/OD230 1.6 and above shows a 
preparation relatively free of organic chemicals and solvents. 
 
c) cDNA Synthesis 
To synthesise cDNA from RNA, first, 1 ug of RNA was incubated with 1 unit 
of DNAse1, in a total volume of 10 l in PCR tube, at 37˚C for 30 min, in a 
thermocycler (GeneAmp PCR System 2700, Applied Biosystem), to digest 
genomic DNA contaminants. After incubation with DNase1, 1 l of RQ1 
DNase Stop Solution (Promega, Mannheim) was added and incubated at 
65˚C for 10 min in the thermocycler, to inactivate the DNase1. Thereafter, 6 l 
and 3 l portions of the mixture were transferred into seperate PCR tubes, 
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labeled +RT and —RT respectively. A volume of 6 l random primer master 
mix (1 l random primer 200 ng/l, 5 l of sterile RNAse-free water) was 
pipetted into the +RT, while 3.5 l was added to the —RT tube. The samples 
were then incubated at 70˚C for 5 min in the thermocycler for random primers 
to anneal to RNA. Next, 8 l of a master mix, containing Reverse Transcriptase 
(M-MLV RT [H—]) (4 l M-MLV 5 buffer, 1 l M-MLV RT [H—](200 U/l), 2 l 
of 10 mM dNTPs, 1 l sterile RNAse-free water) was added to the +RT PCR 
tube, while 4 l of a master mix with no M-MLV RT [H—] (2 l M-MLV 5 
buffer, 1 l of 10 mM dNTPs, 1 l sterile RNAse-free water) was added to the —
RT PCR tube. The tubes were incubated in parallel in the thermocycler using 
the following cDNA synthesis protocol: 
 
cDNA Synthesis Protocol 
Step  Temperature  Time 
1  25°C  10 min 
2  42°C  60 min 
3  70°C  10 min 
4  4°C  Hold 
 
After cDNA synthesis, the content of +RT and —RT PCR were diluted with 80 
l and 40 l sterile RNAse-free water, respectively. Samples were used 
immediately or stored in -20 for future use. 
The +RT tube contains reverse transcriptase for normal cDNA synthesis, 
whereas the —RT, having no reverse transcriptase, serves as quality control 
PCR (QC-PCR), to detect genomic DNA contaminats as decribed below. 
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d) Quality Control PCR (QC-PCR) 
To check for genomic DNA contaminants during RNA extraction, 4 l of the 
+RT and -RT PCR products (Section 2.2.1.2, c) were taken into separate tubes 
and 16 l QC-PCR master mix containing GAPDH gene primers (4 l GoTag 
Polymerase 5x buffer, 0.5 l of 100 nM dNTPs, 1 l forward primer, 1 l 
reverse primer, 0.25 l of GoTag Polymerase, 9.25 l water) added to each 
tube. The samples were incubated in a themocycler (GeneAmp PCR System 
2700, Applied Biosystem) with the QC-PCR protocol below. 
 
QC-PCR Protocol 
Step  Temperature  Time  Number of cycles 
1  95°C  2 min    
2  95°C  2 min  
3  55°C  40 s  
4  72°C  45 s  
5  4°C  Hold    
 
The resultant PCR product were run on agarose gel and visualised (section 
2.2.1.1, c). The presence of DNA fragements in the —RT PCR product indicates 
genomic DNA contamination. 
 
e) Quantitative Real-Time PCR (qRT-PCR) 
To carry out gene expression analysis using qRT-PCR, 4 μl of cDNA (+RT PCR 
product, obtained from Section 2.2.1.2 c) was pipetted into qRT-PCR plates 
(Steinbrenner Laborsysteme, Wiessenbach). Next, 16 μl of qRT-PCR master 
mix containing gene specific primers (10 l SYBR Green qPCR-Mix (Promega), 
1 l forward primer, 1 l reverse primer, 4 l RNase-free water) was added to 
the cDNA. The qRT-PCR was run in StepOnePlus (Life Technologie, Carlsbad, 
California), with an initial denaturation stage carried out at 95°C for 15 min. 
This was followed by 40 cycles of a two-step stage of 95˚C for 15 s, and 60˚C 
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for 30 s, for hybridisation and amplification, and finally, a melting curve with 
a starting temperature of 60˚C, with incremental increase of 0.5˚C to 95˚C, that 
was maintained for 15 s. The relative mRNA expression of a target gene was 
calculated as 2^-(CT (target gene) - CT (reference gene)). 
 
 
2.2.2 PROTEIN ANALYSIS 
 
2.2.2.1  Preparation of Whole Cell Lysate 
BMMCs (2-3  106 cells/ml in medium) were centriguged at 2000 rpm 
(Eppendorf Centrifuge 5417R, Eppendorf AG, Hamburg) for 5 min to pellet 
the cells. The medium was discarded, and the cell pellet was washed with 1 ml 
of cold 1 PBS, by centrifugation at 2000 rpm for 5 min. After washing, cells 
were suspended in 200 l of 2 SDS sample buffer (160 mM Tris-HCl pH 6.8, 
4% SDS, 20% glycerol, 12.5% mM EDTA pH 8.0, 2% β-mercaptoethanol, 0.02% 
bromophenol blue) and incubated at 95˚C in a heating block (Eppendorf 
Thermomixer 5436, Eppendorf-Netheler-Hinz— GmbH, Hamburg) for 5 min. 
After heating, the lysate was centrifuged at 10000 rpm for 5 min and sonicated 
at an amplitude of 50, 5 pulses (Branson Sonifier Cell disrupter B 15 
G.Heinemann Ultraschall- und Labortechnik, Schwäbisch Gmünd). The 
sonified sample was then centrifuged at 10000 rpm at 4 ˚C for 5 min. Volumes 
of 20 l supernatant were loaded in SDS-Polyacrylamide gel for 
electrophoretic separation. 
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2.2.2.2  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
To analyse proteins by SDS-PAGE, a 10% separating gel was used. In this 
method, 25 l of separating gel solution  (9.9 ml dH2O, 8.3 ml 30% 
Arylamide, 6.3 ml of 1.5 M Tris-HCl pH 8.8, 250 l of 10% SDS, 250 l APS, 
10 l TEMED) was poured between two fixed glass plates separated by 
spacers in a gel casting apparatus (Cast-It M caster apparatus, PeqLab 
Biotechnologie GmbH, Erlangen). The top of the gel solution was 
immediately covered with 100% ethanol, and allowed to polymerise at room 
temperature (RT) for 40 min, to form the separating gel. After 
polymerisation, the ethanol was washed away with distilled water and the 
top of the gel overlaid with 8 ml starking gel solution (5.5 ml dH2O, 1.3 ml of 
30% acrylamide, 1 ml of 1.5 M Tris-HCl pH 6.8, 80 l of 10% SDS, 80 l APS, 
8 l TEMED). A comb was placed immediately into the starking gel solution 
to make wells of appropriate depth. The starking gel was allowed to 
polymerise for 20 min. The comb was removed after polymerisation and the 
gel placed in a vertical running chamber (PerfectBlue Dual Gel System Twin 
M Peqlab, Biotechnologie GmbH, Erlargen) filled with 1 Laemmli running 
buffer (25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS). The surface of 
the gel was well covered with the 1x Laemmli running buffer. The first well 
was loaded with 5 l protein molecular weight marker (PageRuler 
Prestained Protein Ladder, 10-180 kDa, Thermo Fischer Scientific Inc., 
Rockford, USA). Thereafter, 20 l of protein sample prepared in 2x SDS 
sample buffer (section 2.2.2.1) was loaded into wells. 
The protein separation was first run at 90V, for proteins to run equally 
through the starking gel, and then increased to 160V, for proteins to separate 
in the separating gel. 
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2.2.2.3  Transfer of Proteins onto Membranes 
The proteins in SDS-polyacrylamide gels were transferred onto PVDF 
(polyvinylidene fluoride) membranes (Merck Millipore, Darmstadt, Germany) 
in an electrophoretic wet-transfer chamber (BioRad, Heidelberg).  
To do this, the membrane was activated by soaking it in methanol for 10 s, and 
placed above the gel, which was already laid on three layers of wet filter 
paper, in a cassette. The membrane was thereafter covered with another three 
layers of filter paper. The cassette was placed in a transfer chamber filled with 
Western blot transfer buffer (25 mM Tris-base, 192 mM glycine, 10% 
methanol). The transfer was carried out at 35V at 4˚C overnight. 
 
2.2.2.4  Immunoblotting and Visualisation of Proteins 
For immunoblotting, membranes were cut into pieces according to molecular 
weight of interest. The membranes were then blocked in 5% milk dissovlved 
in 1x TBST (Tris buffered saline with Tween-20) (20 mM Tris-base, 150 mM 
NaCl, 0.05% Tween-20, pH adjusted to 7.6) for 1h. Thereafter, the membranes 
were incubated overnight with primary antibody at 4˚C. After incubation, 
the membranes were washed three times at 10 min intervals with 10 ml 1x 
TBST, with gentle shaking on a shaker (Heidolph Instuments, Polymax 1040) 
- to wash off unbound primary antibody. Membranes were then incubated 
with secondary antibodies for 30 min at room temperature (RT), after which 
unbound secondary antibody was washed off with 10 ml 1x TBST. 
To visualise the proteins, the surface of the membrane was covered with 
enhanced chemiluminiscence (ECL) Western blotting substrate (Biorad, 
Heidelberg) and signals detected with ChemDoc Touch imager (BioRad, 
Heidelberg) according to manufacturer instructions. 
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2.2.3 CELL CULTURE METHODS 
 
2.2.3.1  Isolation and Culture of Bone Marrow Derived Mast Cells (BMMCs) 
Male C57BL/6 mice aged 8-10 weeks were sacrificed by cervical dislocation, 
washed in 70% ethanol and femurs and tibia removed into Iscove’s Modified 
Dulbecco’s Medium (IMDM Gibco). The bones (femurs and tibia) were first 
washed in 70% ethanol and then in 1x PBS under safety cabinet in S2 cell 
culture laboratory. Thereafter, tips of bones were cut and the bone marrow 
flashed into 50 ml falcon tubes with 20 ml of IMDM per animal, using a 20 ml 
syring and 24-gaige needle. 
The cell suspension was centrifuged at 1300 rpm for 10 min (Eppendorf 
Centrifuge 5804, Eppendorf AG, Harmburg) to pellet the cells. The 
supernatant was discarded and the cell pellet was washed with 5 ml IMDM by 
centrifugation at 1300 rpm for 10 min. The washed pellet was then 
resuspended in 400 l ACK lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 1 mM 
EDTA, pH adjusted to 7.3) for 2 min to lyse red blood cells (RBCs). After lysis, 
8 ml IMDM was added to inactivate the ACk lysis buffer. The resulting cell 
suspension was then passed through a cell strainer (Corning, Kaiserslauten) 
to remove debris. The seived cell suspension was centrifuged at 1300 rpm for 
10 min to pellet the cells. The cell pellet obtained was suspended in 20 ml 
BMMCs medium (IMDM supplemented with 10% FBS, 2 mML-glutamine, I 
mM pyruvate, 100 ng stem cell factor/kit ligand, 5 ng/ml IL3, 50 M β-
mecaptoethanol, 1% penicillin/streptomycin 10000 U/ml) in CELLSTAR T-
75 flask (Greiner Bio-One GmbH, Frickenhausen). Cells were cultured at 37˚C, 
5% CO2 and 95% humidity in an incubator (C 200, Labotech, Göttingen, 
Germany). BMMC medium was changed every three days. To do this, cell 
suspension was centrifuged at 1300 rpm for 7 min, to pellet the BMMCs, since 
BMMCs are suspension cells. Cells were then counted with an Improved 
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Neubauer haemocytometer under light microscope, and re-cultured in BMMC 
medium at a maximum concentration of 2  106 cells/ ml. Cells were used at 4-
7 weeks old. 
 
2.2.3.2  Activation of BMMCs 
To activate BMMCs with antigen, cell suspensions of 2-3 x106 cells/ml seeded 
overnight in 24 well cell culture plates (Greiner Bio-One GmbH, 
Frickenhausen) were sensitised by incubation with 0.05 g/ml anti-DNP IgE 
(anti-Dinitrophenol IgE) for 2 h in incubator (C 200, Labotech, Göttingen, 
Germany). Thereafter, DNP-BSA (dinitrophenyl-bovine serum albumin) was 
added to activate cells, and the cells placed back into the incubator for 1 h. To 
stop the DNP action, cells were picked from the incubator and placed on ice. 
For treatment with dexamethasone (Dex) or the PEP inhibitor L75NO4, seeded 
cells were pretreated for selected time intervals with DEX or L75NO4 or both 
Dex and L75NO4, before sensitisation and activation. 
 
2.2.4 CALCIUM MEASUREMENTS 
Intracellular free Ca2+ concentration [Ca2+]i was measured in 5-7 weeks old 
BMMCs in 2 mM calcium containing physiological solution (135 mM NaCl, 6 
mM KCl, 2 mM CaCl2, 1.2 mM MgCl2, 12 mM glucose, 10 mM HEPES), or 0.1 
mM calcium containing physiological solution (135 mM NaCl, 6 mM KCl, 0.1 
mM CaCl2, 1.2 mM MgCl2, 12 mM glucose, 10 mM HEPES), or norminally 
calcium free solution (135 mM NaCl, 6 mM KCl, 1.2 mM MgCl2, 12 mM 
glucose, 10 mM HEPES) where necessary. For measurements of the antigen-
induced [Ca2+]i elevation, the cells were sensitised overnight with 300 ng/ml 
of anti—DNP IgE (anti-dinitrophenol IgE) in BMMCs medium and cultured at 
37C/95%O2/5%CO2 in cell culture incubator (Solis-Lopez et al. 2017). After 
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sensitisation, cells were loaded with the calcium dye Fura-2 AM (Invitrogen, 
Katalog-Nr F-1221), by suspending cells in 2 μM Fura-2 AM (dissolved in 2 
mM calcium containing physiological solution) at room temperature (RT) for 
30 min. The cell suspension was transferred onto poly-L-lysine-coated 
coverslips and cells allowed to adhere to coverslips during Fura-2 AM loading 
time. Excess dye and unattached cells were washed twice with physiological 
solution. For activation of BMMCs with DNP-HSA (dinitrophenyl-human 
serum albumin), the DNP-HSA was dissolved in the appropriate physiological 
solution and released onto the attached cells on the glass slides when 
necessary. To measure [Ca2+]i levels, the cells were alternatively illuminated 
with excitation light of 340 nm and 380 nm using a monochromator-based 
light source, Polychrom V (TILL Photonics, Germany). The fluorescence 
intensity was measured at 510 nm using Rolera EM-C2 EMCCD Camera 
(QImaging, Canada) and quantified using Axiovision (Zeiss, Germany) 4.82 
software. Signal was acquired every 5 s. The [Ca2+]i level was estimated based 
on 340/380 ratio. For each experiment, cytosolic [Ca2+]i in non-activated cells 
was measured for about 100 s to determine basal level [Ca2+]i, after which cells 
were stimulated with physiological solution containing DNP-HSA 100 ng/ml, 
to measure antigen-induced [Ca2+]i elevation. To measure the calcium 
releasing response from the pharmacological agent, thapsigargin, 2 M 
thapsigargin was made in physiological solution and used in place of DNP-
HSA to activate the cells. For dexamethasone treatment, cells were 
concurrently treated with IgE and dexamethasone in BMMC medium, and 
then placed back into the incubator for 24 h, before activation with DNP-HSA. 
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2.2.5 RNA-SEQUENCING (RNA-SEQ) AND ANALYSIS 
Total RNA was extracted from 3  106 cells for PEP+/+ and PEP-/- BMMCs 
using innuPREP RNA Mini Kit (Analytik Jena AG, Jena, Germany). RNA 
samples were first tested on RNA nanochips (Bioanalyzer 2100, Agilent) to 
ensure there was no sign of degradation. A total of 1 μg RNA was used to 
prepare mRNA sequencing libraries for each sample using the TruSeq 
stranded mRNA kit v2 (Illumina), according to the vendor protocol. Next, 10 
pM of multiplexed libraries were used to generate clusters in 2 lanes of a high-
throughput flowcell. HiSeq 1500 was used to obtain paired-end reads of 50 bp 
using the SBS v3 kit (Illumina). The cluster dectection and the base calling 
were done with the software RTA (v1.13) and demultiplexing with the 
software CASAVA 1.8.1 (Illumina). The sequencing resulted in 576 million 
reads with a mean quality Phred score of 35.2. The quality of the sequencing 
data were first assessed with FASTX toolkit (v0.0.13 
[http://hannonlab.cshl.edu/fastx_toolkit/]) and no pre-processing was 
needed. The alignment of the reads was done with Tophat2 v2.0.11 (Kim et al. 
2013) against the mouse reference genome (GRCm38 v75). The raw counts per 
gene were calculated using HTSeq v0.5.3 (Anders et al. 2014). The 
normalization of the counts, the differential expression analysis and the 
downstream analysis was done using the R software packages (including 
DESeq2 (Love et al. 2014), and also other publicly available packages such as 
‘Database for Annotation, Visualization and Integrated Discovery’ (DAVID 
Bioinformatics Resources 6.8, NIAID/NIH) (Huang et al. 2007a; Huang et al. 
2007b) and Functional Enrichment Analysis Tool (FunRich) (Pathan et al. 
2015). 
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2.2.6 IN VIVO METHODS 
 
2.2.6.1  Passive Systemic Anaphylaxis in BALB/c Mice 
Female 7 months old BALB/c mice (20-25 g) were sensitised by intra-
peritoneal injection (IP) of anti-DNP IgE (1 mg/kg) for 24 h. Anaphylaxis was 
induced by intravenous injection (IV) of 200 μl DNP-HSA (dinitrophenyl-
human serum albumin 1 mg/ml in PBS) into the dorsal caudal vein (vena 
coccygealis dorsalis). Thereafter, abdominal body temperature was measured 
with a vertinary fever thermometer (Micro-life VT 1831 Vet-Temp, Tiershop, 
Trier, Germany) every 5 min for 60 min. 
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Chapter 3  
RESULTS 
3.1  DELETION OF PEP PROTECTS BALB/C MICE AGAINST 
ANAPHYLAXIS 
Anaphylaxis, is a severe and life threathening form of allergy and a major 
disease condition that is strongly associated with mast cell action (Metcalfe et 
al. 2009). A previous study showed that PEP deficient C57BL/6 mice are less 
susceptible to passive systemic anaphylaxis (PSA) (Obiri et al. 2012), a mast 
cell dependent response (Doyle et al. 2013). This was rather unexpected as loss 
of a phosphatase like PEP is expected to cause increased phosphorylation of 
protein tyrosine kinases (PTKs), which will result in an increased mast cell 
activation and a corresponding increase in PSA in the PEP-/- mice. However, 
since some mast cell mediated response can show marked differences between 
mice of different strains (Finkelman et al. 2005; Noguchi et al. 2005), this 
project investigated whether the role of PEP in PSA is dependent on the 
genetic background of mice. 
First, PEP-/- C57BL/6 mice were crossed with BALB/c mice for 10 
generations to generate a colony of PEP+/+ and PEP-/- in a pure BALB/c 
genetic background. PSA was induced by sensitising mice for 24 h with 
dinitrophenol (DNP)-specific IgE injected intra-peritoneally, after which 
anaphylactic reaction was triggered by intravenous injection of DNP. 
Anaphylaxis causes a fall in body temperature that was measured at 5 min 
intervals over a period of 60 min. 
The graph of the anaphylactic response depicted in Figure 3.1A, showed that 
DNP triggered a sharp fall in body temperature in both PEP+/+ and PEP-/- 
mice with a peak reduction at about 20 min of DNP treatment, followed by a 
partial recovery from about 40 min post DNP treatment. Quantification of the 
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diferences in the anaphylactic response between PEP+/+ and PEP-/- mice 
determined by the area under the curve (AUC) (Figure 3.1B) showed that the 
anaphylactic response was about 1.5 -2 fold lower in the PEP-/- BALB/c mice 
compared to the PEP+/+ mice. The finding that PEP-/- BALB/c mice are less 
susceptible to anaphylaxis is in agreement with previous report by Obiri and 
colleagues that PEP-/- C57BL/6 mice are less susceptible to anaphylaxis (Obiri 
et al. 2012). Thus the contribution of PEP to anaphylaxis is not restricted to 
C57BL/6 mice, and PEP appears to be an essential regulator of anaphylaxis. 
However, when the present study was compared to the work of Obiri and 
colleagues, the C57BL/6 mice were more sensitive to anaphylaxis than the 
BALB/c mice. Thus, C57BL/6 mice were used in all the subsequent 
experiments carried-out in this project. 
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Figure 3.1 Deletion of PEP protects BALB/c mice against anaphylaxis: Seven months old 
female mice (20–25g) were sensitised by intraperitoneal injection with dinitrophenol (DNP) 
specific IgE (1 mg/kg) for 24h. Anaphylaxis was then induced with intravenous injection of 200 
µl of DNP 1 mg/ml in phosphate-buffered saline (PBS). Body temperature was measured every 
5 min over a period of 60 min. A, shows the curve of temperature changes over time and B, the 
total anaphylactic response calculated in arbitrary units as Area under the curve (AUC) with 
temperature zero (0) as reference. * p< 0.05, ** p< 0.01, for unpaired two-tailed t-test. (n=6). 
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3.2 PEP DEFICIENT BMMCS SHOW REDUCED INTRACELLULAR 
CALCIUM MOBILISATION IN RESPONSE TO ANTIGEN 
Binding of DNP to the high affinity IgE receptor (FcRI) on mast cells triggers 
signalling pathways that function synergistically to stimulate mast cell effector 
functions such as degranulation, which is key to anaphylaxis (Metcalfe et al. 
2009). A hallmark of FcRI-mediated degranulation is intracellular Ca2+ Ca2+i 
mobilisation (Baba et al. 2008; Harvima et al. 2014).  
This current work used live cell Ca2+ imaging in BMMCs - generated from 
bone marrow progenitor cells from femurs of 8-10 weeks old PEP+/+ and 
PEP-/- mice, cultured in IL-3 rich medium in the presence of c-KIT ligand 
(stem cell factor) for 4-7 weeks (Jensen et al. 2006; Stassen et al. 2006) - to 
investigate the role of PEP in Ca2+i mobilisation in mast cells. 
 
BMMCs were sensitised overnight with DNP-specific IgE and thereafter 
loaded with Ca2+ sensitive dye in medium (2 mM Ca2 physiological medium) 
containing the ratiometric dye, Fura-2 AM. Basal level Ca2+i concentration 
was first measured for 100 s, after which cells were activated by treatment 
with antigen (DNP) (Figure 3.2A). Although the two cell types did not show 
any difference in basal level Ca2+i mobilisation, activation of the cells with 
DNP resulted in a transient rise in Ca2+i, followed by a plateau phase 
charactarised by a gradual decrease in Ca2+i levels. The PEP-/- cells exhibited 
significant drop (34%, p 0.001) in Ca2+i mobilisation as shown by the time 
curve (Figure 3.2A) and the quantification of total Ca2+i from the area under 
the time curve (AUC) (Figure 3.2B). This shows that PEP promotes Ca2+i in 
mast cells.  
The role of PEP in Ca2+i regulation was therefore further investigated. 
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3.3 PEP MODULATES FCRI SIGNALLING TO REGULATE CALCIUM 
MOBILISATION IN BMMCS  
The current study and a previous report (Obiri et al. 2012) do show that 
activated PEP-/- BMMCs have reduced Ca2+i levels, but, as to whether this 
impairment of Ca2+i levels occurs via reduced antigen receptor (FcRI) 
signalling or via FcRI-independent effects, has not been clearly demonstrated. 
 
To determine the mode of Ca2+i impairment in the PEP-/- BMMCs, 
thapsigargin (TG), a pharmacological agent that raises Ca2+i levels 
independent of FcRI (Huber et al. 2000; Bird et al. 2008) was employed. 
 
The mechanism of Ca2+ mobilisation in mast cells depends on Ca2+ release 
from intracellular stores mainly from the endoplasmic reticulum (ER) and Ca2+ 
Figure 3.2 PEP deficient BMMCs have reduced Ca2+ mobilisation: (A) PEP+/+ and PEP-/- BMMCs 
were sensitized overnight with dinitrophenol human serum albumin (DNP-HSA)-specific IgE (300 
ng/ml). Basal level Ca2+i concentration was measured before activation with DNP-HSA (100 ng/ml) in 
optimal (2mM) Ca2+ physiological medium. Ca2+i concentration was measured ratiometrically 
(340/380) at 20 s cycles using Fura-2 AM fluorescence dye. (B) shows total cytosolic Ca2+ levels 
determined by the area under the curve (AUC) for A. F340/380 is the ratio of Ca2+ dye fluorescence 
intensity at 340 and 380 nm light excitation. The result is presented as mean ± standard error of mean. 
*** p< 0.001, for unpaired two-tailed t test (n=3). 
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inﬂux into the cell through Ca2+ channels in the plasma membrane (Parekh and 
Penner 1997; Parekh and Putney 2005; Bird et al. 2008). Thapsigargin triggers 
increased levels of Ca2+i by intracellular store release, via its inhibition of the 
ER Ca2+ regulating pump, the ER Ca2+-ATPase. The ER Ca2+-ATPase maintains 
Ca2+ equilibrium by pumping Ca2+ that is normaly leaked from the ER into the 
cytosol, back into the ER (Clapham 2007; Bird et al. 2008). Inhibition of this 
pump by thapsigargin causes ER Ca2+ extrusion into the cytosol leading to 
increased Ca2+i levels (Bird et al. 2008). 
 
To check the effect of PEP deletion on Ca2+i mobilisation, basal level Ca2+i 
was first measured in 2 mM Ca2+ physiological solution for 100 s, after which 
Ca2+i levels were measured in the presence of thapsigargin (2 M) under 3 
different conditions: a = norminally free Ca2+ physiological solution, b = 0.1 
mM Ca2+ physiological solution, and c = 2 mM Ca2+ physiological solution) 
(Figure 3.3). Ca2+ mobilisation in ‘a’ depicts Ca2+ released from the ER, ‘b’ 
shows Ca2+ from ER and entry through highly sensitive membrane channels, 
and ‘c’ for maximal Ca2+ mobilisation from the ER, highly sensitive channels 
and less sensitive membrane channels.  
In all three cases, there was no difference in the increase in Ca2+i in both 
PEP+/+ and PEP-/- BMMCs indicating no change in FcεRI independent 
mechanisms of Ca2+ regulation. Hence, the reduced Ca2+i mobilisation in 
DNP treated PEP-/- cells is likely due to modulation at the level of FcRI-
mediated signalling. 
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3.4 GENOMEWIDE EFFECTS OF PEP DEFICIENCY IN BMMCS 
To identify mast cell effector functions that may be affected by PEP gene 
deletion, a transcriptomic approach (RNA-sequencing) was adopted. 
The main goals in this analysis were:  
A. to identify differences in basal (resting) level gene expression between 
PEP+/+ and PEP-/- BMMCs and 
B. to identify differences in antigen-induced gene expression between 
PEP+/+ and PEP-/- BMMCs that may contribute to changes in mast 
cell effector functions. 
PEP+/+ and PEP-/- BMMCs were sensitised with dinitrophenol (DNP)-
specific IgE (500 ng/ml) for 2 h after which cells were either left unactivated 
Figure 3.3 PEP gene deletion does not affect thapsigargin (TG)-induced Ca2+ mobilisation: a in 
norminally free Ca2+, b in submaximal extracellular Ca2+ (0.1mM) and c in maximal level of 
extracellular Ca2+ (2 mM). F340/380 is the ratio of Ca2+ dye fluorescence intensity at 340 and 380 nm 
light excitation. The result is presented as the mean at various time points. Thapsigagin was used at 2 
M. 
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(sensitized) or activated with DNP (200 ng/ml) for 1 h. RNA was extracted 
from two replicates each, for four experimental conditions:  
1) IgE sensitised PEP+/+ (basal),  
2) IgE sensitised PEP-/- (basal),  
3) DNP treated PEP+/+ (activated) and  
4) DNP treated PEP-/- cells (activated)  
The gene expression pattern of all the replicates as displayed in a cluster 
heatmap of the normalised expression (variance transformed) shows genes 
with low expression (blue) and high (red) under different conditions of 
treatment (Figure 3.4A). 
 
3.4.1 PEP DEFICIENCY DOES NOT AFFECT BASAL LEVEL GENE 
EXPRESSION 
To identify differences in the pattern of gene expression under basal 
conditions in the two cell types, PEP+/+ IgE (Figure 3.4A, columns 1 and 2) 
was compared with that of the PEP-/- IgE (Figure 3.4A, columns 3 and 4). The 
fold change values (Log2FoldChange) and the level of significance (adjusted 
p-value  0.05, Benjamini-Hochberg) are displayed in a volcano plot to 
highlight genes that are significantly downregulated (blue) or upregulated 
(red) in the PEP-/- compared to the PEP+/+ cells (Figure 3.4B). This analysis 
identified PTPN22 (PEP) as the only gene significantly downregulated in the 
PEP-/- cells compared to PEP+/+ (Figure 3.4B), which means that deletion of 
PEP does not affect basal level gene expression in BMMCs. 
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3.4.2 PEP DEFICIENCY ALTERED ANTIGEN-INDUCED GENE EXPRESSION 
To determine the effect of PEP gene deletion on the antigen response, a three 
step analysis was done: 
(1)  to identify genes that were at least 2 fold misregulated (downregulated 
or upregulated) in the PEP+/+ in response to antigen (DNP) comparing 
PEP+/+ IgE (basal, columns 1 and 2) with PEP+/+ DNP (activated, 
columns 5 and 6). 
(2)  to identify genes that were at least 2 fold misregulated (downregulated 
or upregulated in the PEP-/- in response to antigen (DNP) by 
comparing PEP-/- IgE (basal, columns 3 and 4) against PEP-/- DNP 
(activated, columns 7 and 8) and 
(3) to identify key differences between activated PEP+/+ and PEP-/- cells 
by comparing the output data from analysis (1) and (2). 
The results showed that in both activated PEP+/+ (Figure 3.4C) and PEP-/- 
BMMCs (Figure 3.4D) many more genes were upregulated (red) than were 
downregulated (blue) in response to antigen. In activated PEP+/+ BMMCs, 
461 genes were misregulated of which 55 (11.9%) were down regulated and 
406 (88.1%) were upregulated. Activated PEP-/- BMMCs on the other hand 
showed 769 genes were misregulated in response to antigen, 162 (21.1%) being 
down regulated and 607 (78.9%) being upregulated. What is striking is that 
there were almost twice as many genes misregulated (down or upregulated) in 
response to antigen in the PEP-/- as compared to the PEP+/+ BMMCs, 
indicating that PEP deficiency induces remarkable changes in antigen-
regulated gene expression, showing that PEP is an essential modulator of 
FcRI receptor signalling. 
Analysis to identify differences in the gene expression pattern between 
activated PEP+/+ and PEP-/- BMMCs as illustrated by Venn diagram (Figure 
3.4E) showed that almost all the genes that were misregulated in response to 
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antigen in the PEP+/+ BMMCs were also misregulated in the PEP-/- cells 
except for 9 genes that were uniquely misregulated in the PEP+/+ cells. 
About, 452 genes were common to both PEP+/+ and PEP-/- cells, but as many 
as 317 genes (41.2%) of the total 769 genes misregulated by antigen in PEP-/- 
BMMCs were unique to PEP-/- BMMCs, which shows that deletion of PEP 
induces unique changes in antigen-induced gene regulation. 
The biological significance of these changes was explored in subsequent 
analysis described below. 
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3.4.3 PEP-/- BMMCs SHOWED REDUCED CYTOKINE/CHEMOKINE GENE 
EXPRESSION AND MISREGULATED MAPK SIGNALLING IN RESPONSE 
TO ANTIGEN 
To explore the biological significance of the differences between activated 
PEP+/+ and PEP-/- BMMCs, Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis was carried-out using the publicly available online 
program ‘Database for Annotation, Visualization and Integrated Discovery’ 
DAVID Bioinformatics Resources 6.8, NIAID/NIH (Huang et al. 2007a; 
Huang et al. 2007b). A cut-off criterion of adjusted p-value  0.1 (Benjamini-
Figure 3.4 Deletion of PEP induces changes in gene expression profile of activated BMMCs: A is 
a colour-coded heatmap of the normalised expression level of genes in samples representing two 
replicates each for four different experimental conditions. Genes were hierachically clustered using 
Euclidean distances in the R software packages. The colour gradient shows blue for low and red for 
high expression of genes. B is a volcano plot showing the distribution of genes that are significantly 
(adjusted p value  0.05 ) expressed at least  2 fold lower (blue) or higher (red) in the PEP-/- IgE 
(basal) when compared to PEP+/+ IgE (basal), C shows genes downregulated (blue) or upregulated 
(red) in the PEP+/+ in response to antigen by comparing PEP+/+ DNP (activated) with PEP+/+ IgE 
(basal) and D genes downregulated (blue) and upregulated (red) in the PEP-/- in response to antigen by 
comparing the PEP-/- DNP (activated) with  PEP-/- IgE (basal). E is a scaled Venn diagram showing 
the similarities and differencies in the antigen-induced gene profile between PEP+/+ and PEP-/- 
BMMCs. 
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Hochberg) was used for selection of KEGG pathways of biological 
significance.  
From the results, no KEGG pathway was found for the 9 genes that were 
uniquely misregulated in PEP+/+ in response to antigen, but some of the 317 
genes that were unique to the PEP-/- were associated with KEGG pathways 
although based on the cut-off criterion none of the pathways was significantly 
enriched to be considered as biologicaly important for this analysis (Table 3.1). 
Nevertheless, the assoiated pathways involve immune cell functions such 
leukocyte transendothelial migration, T cell receptor signaling pathway and 
natural killer cell mediated cytotoxicity and also pathways such as MAPK 
signalling which forms an integral part of pathways that mediate immune cell 
functions (Table 3.1). 
For the 452 genes commonly regulated in both cell types, the question was 
asked whether any of these genes show differences in their pattern of 
expression between the PEP+/+ BMMCs and PEP-/- cells. Hence their 
foldchange in response to antigen in the PEP-/- cells was compared with that 
of the PEP+/+ cells. Genes that were found to be expressed at least 1.2 fold 
lower or higher in the PEP-/- were filtered out.  
In all, 138 genes (30.5%) out of the 452 were identified to have higher 
expression in the PEP-/-, while 32 (7.1%) showed lower expression when 
compared to PEP+/+ BMMCs. KEGG pathway analysis using the 32 genes 
that showed low expression in PEP-/- BMMCs identified 11 KEGG pathways 
that were significantly enriched with genes (Table 3.2). FcRI signaling, the 
main pathway activated by antigen in mast cells was one of the pathways 
significantly affected. Associated with the FcRI pathway are 
cytokines/chemokines TNFα, IL13 and CSF2 (GM-CSF), which are 
downstream gene products of FcRI activation (Figure 3.5). 
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Table 3.1 KEGG pathways associated with the 317 genes uniquely misregulated in PEP-/- cells in 
response to antigen. (Benjamini-Hochberg Adjusted p-value  0.1, considered as significant). 
 
 
Table 3.2 KEGG pathways associated with the 32 commonly regulated antigen responsive genes 
identified to have lower expression in PEP-/- DNP treated BMMCs compared to PEP+/+ DNP 
treated cells. (Benjamini-Hochberg Adjusted p-value  0.1, considered as significant). 
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KEGG analysis of the 138 (30.5%) commonly regulated genes that show higher 
expression in PEP-/- BMMCs identified MAPK signalling, which is part of 
FcRI signalling, as the only significantly enriched pathway of importance 
(Table 3.3). The MARK pathway was associated with 11 genes. Seven (7) 
(DUSP2, FOS, GADD45B, JUND, MAP3K8, NR4A1, PDGFA) that could 
promote MAPK signalling and thus enhance inflammation, and four (4) others 
(DUSP1, DUSP4, DUSP5, DUSP8) which are all dual-specificity phosphatases 
(DUSP/MKP) that negatively regulate MAPK signalling (Figure 3.6). 
Therefore in the absence of PEP there is compensatory upregulation of genes 
that can activate MAPK signalling and genes that inhibit MAPK signalling. 
 Figure 3.5 Deletion of PEP induces changes in the gene expression profile of activated BMMCs: KEGG 
pathway analysis using the 32 commonly regulated antigen responsive genes that showed lower expression in 
PEP-/- BMMCs identified cytokine/chemokine genes involved in FcRI signalling. 
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Table 3.3 KEGG pathways associated with 138 commonly regulated antigen responsive genes 
identified to have higher expression in PEP-/- BMMCs compared to PEP+/+ cells. (Benjamini-
Hochberg Adjusted p-value  0.1 considered as significant). 
 
 
 
 
 
Figure 3.6 MAPK pathway is misregulated in PEP-/- cells in response to antigen in BMMCs: KEGG 
pathway analysis using the 138 commonly regulated antigen responsive genes that show higher expression in 
PEP-/- cells, identified 7 genes (DUSP2, FOS, GADD45B, JUND, MAP3K8, NR4A1, PDGFA) that can 
upregulate MAPK signalling and 4 genes (DUSP1, DUSP4, DUSP5, DUSP8) that can downregulate MAPK 
signalling. 
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As secretion of cytokines/chemokines is a key mast cell function, the 
cytokine/chemokine genes TNFα, IL13 and CSF2 (GM-CSF) which showed 
reduced expression in PEP-/- cells were subsequently validated using gene 
specific primers in quantitative real-time PCR (qRT-PCR) analysis. 
 
3.4.4 VALIDATION OF CYTOKINE/CHEMOKINE GENES THAT SHOW 
REDUCED EXPRESSION TO ANTIGEN IN PEP-/- BMMCs 
Quantitative real-time PCR (qRT-PCR) was used to validate the expression of 
cytokine/chemokine genes TNF, IL13 and CSF2 (GM-CSF) that were 
selectively affected by PEP gene deletion. 
BMMCs from PEP+/+ and PEP-/- mice were sensitized with DNP specific IgE 
(500 ng/ml) for 2 h and thereafter activated with DNP (200 ng/ml) for 1 h. 
RNA isolated from the cells were then reverse transcribed to cDNA and 
subjected to qRT-PCR analysis with gene specific primers. 
The results showed no significant change in the basal level gene expression. 
However, antigen (DNP) treatment increased the expression of 
cytokine/chemokine genes in both cell types, with PEP-/- cells, showing 
lower expression in response to antigen compared to the PEP+/+ BMMCs in 
all the genes analysed. This shows that PEP is needed for maximal 
cytokine/chemokine production in mast cells (Figure 3.7). 
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3.4.5 INHIBITION OF PEP ACTIVITY CONTRIBUTES TO REDUCED 
CYTOKINE/CHEMOKINE GENE EXPRESSION IN PEP-/- BMMCS 
To determine whether the reduced cytokine/chemokine gene expression in 
PEP-/- BMMCs is due to loss of PEP activity or some secondary effects, qRT-
PCR experiments were performed with a potent and selective inhibitor of PEP 
activity. The inhibitor, L75NO4, was shown by He and colleagues to interact 
Figure 3.7 PEP-/- BMMCs have reduced cytokine/chemokine gene expression in response to antigen 
(DNP). Gene expression pattern of cytokine/chemokine genes identified to be differentially misregulated in 
response to DNP upon PEP gene deletion were analyzed by qRT-PCR. BMMCs were sensitized with anti–
dinitrophenyl bovine serum albumin (DNP-BSA) IgE (500 ng/ml) for 2 h. After sensitization, cells were 
activated with DNP-BSA (200 ng/ml) for 1 h. RNA isolated from the cells were then reverse transcribed to 
cDNA and subjected to qRT-PCR analysis with gene specific primers. Results are presented as the mean ± 
standard error of mean. * p< 0.05, *** p< 0.001 for unpaired two-tailed t test (n=3). 
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with the catalytic pocket of PEP to inhibit PEP activity, leading to reduced 
anaphylaxis and mast cell degranulation in PEP-/- mice and BMMCs 
respectively (He et al. 2013). 
 
BMMCs were treated with L75NO4 (5 M) for 6 h after which cells were 
sensitized with IgE (500 ng/ml) for 2 h and subsequently activated with the 
antigen DNP (200 ng/ml) for 1 h. RNA extracted from the cells were reverse 
transcribed to cDNA for qRT-PCR quantification using TNFα as representative 
cytokine/chemokine gene. 
The results showed that inhibition of PEP catalytic activity in PEP+/+ BMMCs 
with L75NO4 caused reduced TNFα gene expression in response to antigen 
(Figure 3.8A), just as was observed for the PEP-/- cells with no inhibitor 
(Figure 3.8B). Treatment of PEP-/- BMMCs with L75NO4 did not affect basal 
nor the antigen response (Figure 3.8C) when compared to PEP-/- BMMCs 
with no inhibitor (Figure 3.8B), showing that the L75NO4 effect on PEP is 
specific, and that PEP is directly involved in the regulation of antigen-induced 
cytokine/chemokine gene expression. 
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Figure 3.8 Inhibition of PEP activity contributes to the reduced cytokine/chemokine gene expression: 
BMMCs were first treated with PEP inhibitor L75NO4 (5 M) for 6 h and thereafter sensitised with IgE (500 
ng/ml) for 2 h and subsequently activated with the antigen DNP (200 ng/ml) for 1 h. RNA extracted from the 
cells was reverse transcribed into cDNA for qRT-PCR quantification of TNFα. Results are presented as the 
mean ± standard error of mean. * p< 0.05, ns (not significant), for unpaired two-tailed t test. (n=3). 
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3.5 PEP EXPRESSION IS UPREGULATED BY GLUCOCORTICOIDS 
Glucocorticoids (GCs) inhibit mast cell functions and upregulate PEP 
expression in bone marrow derived mast cells (BMMCs) (Maier et al. 2007; 
Obiri et al. 2012). To investigate the possibility that GC-mediated regulation of 
mast cell functions involve PEP, there is the need to establish effective time 
points for GC-induced PEP expression. This experiment was carried out by 
treating cells with Dex (10-7 M) at given time points (10 min — 24 h). PEP 
expression was then assayed with whole cell lysate in a Western Blotting 
analysis. The results showed that GC induces sustained PEP expression from 
4-24 h (Figure 3.9).  
 
 
 
 
 
 
Having shown that GCs are able to induce PEP expression in BMMCs, the role 
of PEP in GC action in mast cells was further investigated. 
 
 
Figure 3.9 Dexamethasone (Dex) induces PEP expression in BMMCs: PEP+/+ and PEP-/- 
BMMCs were treated with Dex (10-7 M) (+) or vehicle control (-) at indicated time points (10 min – 
24 h). Whole cell lysates were subjected to Western blot analysis using specific antibodies for PEP 
and p38 MAPK as control. NT is naïve non-treated control. Data is a representation of 2 independent 
experiments. 
PEP+/+ 
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3.6 PEP DEFICIENCY DOES NOT AFFECT GLUCOCORTICOID-INDUCED 
DOWNREGULATION OF CALCIUM MOBILISATION 
Glucocorticoids (GCs) exhibit antiallergic/antiinflammatory effects by 
downregulating mast cell effector functions (Daeron et al. 1982; Oppong et al. 
2013). Inhibition of signalling pathways that mediate Ca2+ mobilisation is one 
mechanism by which GCs downregulate mast cell functions (Obiri et al. 2012). 
As preceeding investigations in this work showed that PEP is involved in Ca2+ 
mobilisation, the question was asked whether PEP is also involved in GC-
induced downregulation of Ca2+ mobilisation. 
To answer this question Ca2+ mobilisation in GC treated PEP-/- BMMCs was 
compared to GC treated PEP+/+ cells. BMMCs bathed in Ca2+ (2 mM) 
containing physiological solution were simultaneously sensitised with DNP 
specific IgE (300 ng/ml) and treated with either vehicle control (Eth) or 
dexamethasone (Dex) for 24 h. Thereafter, cells were loaded with the Ca2+ 
sensing dye Fura-2 for 30 min. Thereafter, basal level Ca2+i was measured in 
resting mast cells for 100 s. The results showed that basal level intracellular 
calcium Ca2+i was not significantly different between the experimental 
groups (Figure 3.10A). Treatment of BMMCs with the antigen DNP triggered 
rapid increase in Ca2+i levels in all the experimental groups (Figure 3.10A) 
with the PEP-/- vehicle control (PEP-/- Eth) showing lower Ca2+i levels 
when compared to the PEP+/+ vehicle control (PEP+/+ Eth). On the hand, 
Ca2+i levels were downregulated in the BMMCs treated with DEX with no 
difference between PEP-/- cells treated with Dex when compared to the 
PEP+/+ treated with Dex (Figure 3.10A). 
Quantification of the total Ca2+i mobilisation from area under the time curve 
(AUC) (Figure 3.10B) confirmed that antigen (DNP) treated PEP-/- BMMCs 
have reduced Ca2+i mobilisation in response to antigen when compared to 
PEP+/+ cells (Figure 3.10B). Nevertheless, deletion of PEP did not affect the 
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ability of GC to downregulate Ca2+i mobilisation (Figure 3.10B), meaning that 
negative regulation of Ca2+i mobilisation by GCs does not involve PEP. 
 
 
 
 
 
 
 
 
As GCs also downregulate cytokine/chemokine gene expression, the 
involvement of PEP in this process was analysed. 
 
 
Figure 3.10 PEP deficiency does not impair GC-induced negative regulation of Ca2+ 
mobilisation in BMMCs. PEP+/+ and PEP-/- BMMCs were simultaneously sensitised with DNP-
HSA specific IgE (300 ng/ml) and pretreated with either dexamethasone (Dex) (100 nM) or vehicle 
control (ethanol, Eth) for 24 h before activation with DNP-HSA (100 ng/ml). The cytosolic Ca2+i 
concentration was estimated ratiometrically at two wavelenghs (340/380 nm) using Fura-2 
fluorescence dye. A is the time curve for Ca2+i mobilisation and B shows total Ca2+i levels 
determined by the area under the time curve in A (AUC). Data represent the mean ± standard error of 
mean. *** p< 0.001 for unpaired two-tailed t test ns (not significant) (n= 3). 
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3.7 DELETION OF PEP DOES NOT AFFECT GLUCOCORTICOID-
INDUCED NEGATIVE REGULATION OF CYTOKINE/CHEMOKINE 
GENE EXPRESSION 
PEP+/+ and PEP-/- BMMCs were pretreated with Dex (10-7 M) for 5 h and 
sensitized with DNP specific IgE (500 ng/ml) for 2 h. After sensitization, cells 
were activated with DNP (200 ng/ml) for 1 h. RNA isolated from the cells 
were then reverse transcribed to cDNA for qRT-PCR analysis with gene 
specific primers for the three cytokines/chemokine genes (IL-13, TNFα, CSF2) 
that were identified to be regulated by PEP. The results showed that antigen 
induces increased expression of these genes and that their expression is down 
regulated by GC to the same level in both the PEP+/+ and PEP-/- BMMCs 
(Figure 3.11), meaning that GC-induced downregulation of these 
cytokines/chemokines does not involve PEP. 
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As GC action on immune cell functions can vary with the dose of GC (Chen et 
al. 2013), the effect of PEP on GC action was analysed in a dose-response 
experiment, with varying concentrations of Dex (10-11-10-6 M), using qRT-PCR 
analysis. Gene expression of TNFα, one of the cytokines/chemokines 
regulated by both GC and PEP in response to antigen, was used as a read-out. 
Treatment of PEP+/+ and PEP-/- BMMCs with antigen and GC was carried 
out as described ealier for section 3.7. 
The results showed that antigen-induced cytokine/chemokine gene 
expression is lower in the PEP-/- BMMCs compared to the PEP+/+ cells, and 
that GCs dose-dependently inhibited the antigen response in both cell types 
Figure 3.11 Glucocorticoid-induced negative regulation 
of cytokine/chemokine genes is not impaired in PEP-/- 
BMMCs. BMMCs were pretreated with dexamethasone 
(Dex) (10-7 M). Five hours (5 h) after Dex treatment, cells 
were sensitized with DNP-BSA specific IgE (500 ng/ml) for 
2 h. After sensitization, cells were activated with DNP-BSA 
(200 ng/ml) for 1 h. RNA isolated from the cells were then 
reverse transcribed to cDNA and subjected to qRT-PCR 
analysis with gene specific primers. The qRT-PCR results 
are presented as the mean ± standard error of mean. * p< 
0.05, ** p< 0.01, ***p< 0.001 for unpaired two-tailed t test 
(n=4-5). 
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(Figure 3.12). EC50 values (effective concentration that produces 50% of 
maximum response) for GC treatment extrapolated from the dose response 
curves were statistically similar for both cell-types (PEP+/+ = 1.89E-10 M, 
PEP-/- = 2.27E-10 M), meaning that PEP may not play a role in GC-induced 
negative regulation of this cytokine/chemokine expression, in agreement with 
the previous results in Figure 3.11. 
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3.8 RNA-SEQ EXPERIMENT TO INVESTIGATE THE ROLE OF PEP IN 
GLUCOCORTICOID ACTION 
To investigate further the role of PEP in GC action, a global approach using 
RNA-seq experiments were employed. 
Figure 3.12 Deletion of PEP does not affect glucocorticoid-induced regulation of 
cytokine/chemokine gene expression. PEP+/+ and PEP-/- BMMCs were pre-treated with 
dexamethasone (Dex) (10-11 – 10-6 M). Five hours (5 h) after Dex treatment, cells were sensitized 
with DNP-BSA specific IgE (500 ng/ml) for 2 h. After sensitization, cells were activated with 
DNP-BSA (200 ng/ml) for 1 h. RNA isolated from the cells were then reverse transcribed to cDNA 
and subjected to qRT-PCR analysis with gene specific primers for TNFα. The points on the curve 
are presented as the mean ± standard error of mean for unpaired two-tailed t test (n=3). 
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The treatment of cells with GC for RNA-seq analysis was carried out in 
parallel with the RNA-seq experiment for antigen treatment and the analysis 
carried out in a three-step approach: 
(1) to identify genes regulated by GC in antigen treated PEP+/+ cells. 
(2) to identify genes regulated by GC in antigen treated PEP-/- cells. 
(3) to compare the genes identified in (1) and (2), to show genes whose 
regulation by GC is altered due to PEP gene deletion. 
 
3.8.1 DELETION OF PEP ALTERS GLUCOCORTICOID RESPONSE TO 
ANTIGEN IN BMMCS 
RNA-seq gene expression data from PEP+/+ and PEP-/- BMMCs activated 
with DNP were compared with activated cells treated with Dex (10-7 M). 
The gene expression pattern of all the replicates as displayed in a cluster 
heatmap of the normalised expression (variance transformed) shows genes 
with low (blue) and high (red) expression under different conditions of 
treatment (Figure 3.13A). 
PEP+/+ BMMCs treated with the antigen DNP (PEP+/+ DNP, columns 1and 
2) was compared with PEP+/+ cells treated with antigen and Dex (PEP+/+ 
DNP/DEX, columns 5 and 6) to identify antigen regulated genes that are 
expressed at least 2 fold lower (blue) or higher (red) in response to GC in 
PEP+/+ cells (Figure 3.13B). Similarly, DNP treated PEP-/- BMMCs (PEP-/- 
DNP, culumns 3 and 4) was compared with PEP-/- cells treated with DNP 
and GC (DEX) (PEP-/- DNP/DEX, columns 7 and 8) to identify antigen-
regulated genes that respond to GC treatment in PEP-/- BMMCs (Figure 
3.13C). 
About 366 antigen regulated genes in PEP+/+ BMMCs were misregulated by 
Dex, of which 147 (40.2%) were downregulated (blue) while 219 (59.8%) were 
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upregulated (red) (Figure 3.13B). In PEP-/- BMMCs, 382 genes were 
misregulated in response to Dex, 138 (36.1%) being downregulated (blue) 
while 244 (63.9%) were upregulated (red) (Figure 3.13C). 
To identify differences in Dex-induced regulation of gene expression between 
the two cell types, the gene expression pattern between Dex treated activated 
PEP+/+ BMMCs was compared to activated PEP-/- cells treated with Dex. 
The results displayed as Venn diagram (Figure 3.13D) showed that 82 genes 
were uniquely regulated by Dex in the PEP+/+ BMMCs while 98 were 
exclusively regulated by Dex in the PEP-/- cells. On the other hand, 284 genes 
were commonly regulated by Dex in both cell types. Pathway analysis was 
subsequently carried out with these genes to determine the functional 
significance of these differences. 
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Figure 3.13 Deletion of PEP induces changes in 
the GC response to antigen: A is a colour-coded 
heatmap of the normalised expression level of genes 
in eight (8) samples representing two (2) replicates 
for each of four (4) different experimental 
conditions. Genes were hierachically clustered using 
Euclidean distances in the R software packages. The 
colour gradient shows blue for low expression and 
red for high expression. B is a volcano plot showing 
the distribution of genes that are significantly 
(adjusted p value 0.05 ) expressed at least 2 fold 
lower (blue) or higher (red) in the PEP+/+ 
DNP/DEX when compared to PEP+/+ DNP. C 
shows genes downregulated (blue) or upregulated 
(red) in the PEP-/- DNP/DEX when compared to 
PEP-/- DNP. D is a scaled Venn diagram showing 
the similarities and differencies in GC regulated 
genes between DEX treated PEP+/+ and DEX 
treated PEP-/- BMMCs by comparing gene 
expression pattern in B and C. 
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3.8.2 DELETION OF PEP ALTERS GLUCOCORTICOID-INDUCED REGULATION 
OF PTGS2/COX-2 AND PTGDS GENE EXPRESSION 
For the 82 genes uniquely regulated by Dex in PEP+/+ BMMCs, 46 (56.1%) 
were negatively regulated while 36 (43.9%) were upregulated. No KEGG 
pathway was found to be significantly (adjusted p-value  0.1, Benjamini-
Hochberg) enriched with these genes, but the analysis identified amongst 
these 82 genes, prostaglandin-endoperoxide synthase 2/cyclooxygenase 2 
(PTGS2/COX-2), a key enzyme, involved in the production of 
lipid/eicosanoid mediator synthesis and which is a target of GC action. The 
expression of COX-2 was upregulated in both PEP+/+ and PEP-/- BMMCs by 
the antigen DNP, but its negative regulation in the PEP-/- by Dex was 
abrogated, showing that PEP is needed for the negative regulation of COX-2 
by GCs. 
Furthermore, of the 98 genes that were exclusively regulated by Dex in PEP-/- 
cells, 37genes (37.8%) and 61 genes (62.2%) were downregulated and 
upregulated respectively by GC with no associated KEGG pathway. None of 
the genes in this group was identified to be of unique importance to mast cell 
effector functions and GC action, although they are involved in cell signalling. 
 
For the 284 commonly regulated genes, a cut off criterion of 2 fold change 
identified 3 genes (OLFR224, PTGDS, SLC28a2) whose expression is 
upregulated in Dex treated PEP-/- cells when compared to Dex treated 
PEP+/+ cells. Although these genes were also not enriched in any KEGG 
pathway, one of the genes in this group, PTGDS (lipocalin-type prostaglandin 
D2 synthase), is an isomerase that promotes lipid mediator synthesis by 
converting COX-2 derived PGH2 (prostaglandin H2) to PGD2 (prostaglandin 
D2) (Figure 1.2). As the RNA-seq results show that PEP is needed for GC-
RESULTS  
 64  
induced regulation of PTGS2/COX-2 and PTGDS, the expression of these 
genes were validated in a qRT-PCR analysis. 
 
3.8.3 QUANTITATIVE REAL-TIME PCR ANALYSIS CONFIRMED IMPAIRMENT 
OF GLUCOCORTICOID-INDUCED REGULATION OF PTGS2/COX-2 AND 
PTGDS EXPRESSION BY PEP GENE DELETION 
To validate the effect of PEP gene deletion on GC-induced regulation of 
PTGS2/COX-2 and PTGDS gene expression, BMMCs were treated with Dex 
and the antigen DNP as described for the RNA-seq analysis in section 3.8. The 
results showed that antigen induces increased expression of PTGS2/COX-2 in 
both PEP+/+ and PEP-/- cells (Figure 3.14A), with the PEP-/- BMMCs 
showing decresed PTGS2/COX-2 expression in response to antigen (Figure 
3.14A), meaning that PEP is needed for antigen-induced PTGS2/COX-2 
expression. On the other hand, whereas Dex significantly reduces the antigen 
response in PEP+/+ BMMCs, the Dex response in the PEP-/- cells was lost 
(Figure 3.14A), suggesting that PEP is needed for GC-mediated negative 
regulation of antigen-induced COX-2 gene expression. 
Furthermore, both PEP+/+ and PEP-/- BMMCs showed low expression of 
PTGDS in activated cells. However, Dex treatment upregulated the expression 
of PTGDS gene in both PEP+/+ and PEP-/- BMMCs, but the upregulation of 
PTGDS expression was enhanced by PEP gene deletion, as Dex treated PEP-/- 
BMMCs showed significantly higher PTGDS levles when compared to Dex 
treated PEP+/+ cells (Figure 3.14B). The implication of PTGDS upregulation in 
PEP-/-BMMCs cannot be easily deduced from the current analysis, because 
this isoform of prostaglandin D2 synthase is not known to be active in immune 
cells such as mast cells (Urade and Hayaishi 2000; Firestein et al. 2015). But, 
altogether, the results show that PEP is needed for GC-induced negative 
regulation of lipid mediator synthesis in mast cells. 
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3.8.4 INHIBITION OF PEP ACTIVITY CONTRIBUTES TO IMPAIRED 
GLUCOCORTICOID RESPONSE 
To determine whether the impairment of GC-induced regulation of lipid 
mediator synthesis involves direct PEP activity, GC-induced negative 
regulation of COX-2 expression was analysed in BMMCs treated with the PEP 
inhibitor L75NO4. 
In this analysis, PEP+/+ and PEP-/- BMMCs were pretreated with the 
L75NO4 for 1 h, after which cells were either treated with ethanol (vehicle 
control) or Dex (10-7 M) for 5 h. Thereafter, cells were sensitized with IgE (500 
ng/ml) for 2 h and activated with the antigen DNP (200 ng/ml) for 1 h. RNA 
extracted from these cells were reverse transcribed to cDNA for qRT-PCR 
quantification using gene specific primers for COX-2. 
Figure 3.14 GC-induced regulation of PTGS2/ COX-2 and PTGDS is impaired in PEP-/- BMMCs. 
BMMCs were pretreated with dexamethasone (Dex) (10-7 M). Five hours (5 h) after GC treatment, cells 
were sensitized with DNP-BSA specific IgE (500 ng/ml) for 2 h. After sensitization, cells were activated 
with DNP-BSA (200 ng/ml) for 1 h. RNA isolated from the cells were then reverse transcribed to cDNA 
and subjected to qRT-PCR analysis with gene specific primers. The qRT-PCR results are presented as the 
mean ± standard error of mean. * p< 0.05, ** p< 0.01 for unpaired two tail t test (n=5). 
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The results showed that inhibition of PEP activity wth L75NO4 in PEP+/+ 
BMMCs caused reduced DNP-induced COX-2 gene expression (Figure 3.15A), 
just as was observed for the PEP-/- cells with no inhibitor (Figure 3.15B). Also, 
treatment of PEP-/- BMMCs with L75NO4 did not affect the antigen response 
when compared with PEP-/- BMMCs with no inhibitor (Figure 3.15C), 
showing that L75NO4 is specific. 
 
The results also showed that inhibition of PEP activity with L75NO4 in 
PEP+/+ BMMCs abolished the Dex-induced negative regulation of COX-2 
gene expression (Figure 3.15D), similar to what was observed for the PEP-/- 
cells treated with Dex (Figure 3.15E). Incubation of Dex treated PEP-/- 
BMMCs with L75NO4 did not cause any significant change in the Dex 
response when compared with Dex treated PEP-/- BMMCs with no inhibitor 
(Figure 3.15F), which further confirms that L75NO4 is specfic. 
All together, the above observations showed that PEP is important for GC-
induced negative regulation of lipid mediator synthesis in mast cells. 
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Figure 3.15 Inhibition of PEP phosphatase activity contributes to impaired GC-induced PTGS2/ COX-2 
regulation in BMMCs. BMMCs were first treated with the inhibitor L75NO4 (5 uM) for 1 h. After 1 hour 
cells were either treated with ethanol control or dexamethasone (Dex) (10-7 M) for 5 h. After 5 h of Dex 
treatment, cells were sensitized with IgE (500 ng/ml) for 2 h and then activated with the antigen DNP (200 
ng/ml) for 1 h. RNA extracted from the cells were reverse transcribed to cDNA for qRT-PCR quantification. 
The results are presented as the mean ± standard error of mean.* p< 0.05, *** p< 0.001, ns (not significant) 
(n=4). 
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Chapter 4  
DISCUSSION 
4.1 GENERAL DISCUSSION 
PEP is a protein tyrosine phosphatase exclusively expressed in immune cells 
(Bottini and Peterson 2014), including mast cells (Maier et al. 2007). Disease 
associated studies showed that single nucleotide polymorphism (SNP) in the 
human orthologue of PEP (LYP) is a risk fatcor for chronic inflammatory 
conditions, notably rheumatoid arthritis (Vang et al. 2008; Bottini and Peterson 
2014; Stanford and Bottini 2014), for which glucocorticoids (GCs) such as 
dexamethasone are employed as part of a repertoire of therapeutic agents 
(Kirwan et al. 2007). Interestingly, PEP was found to be up regulated by 
dexamethasone in mast cells (Maier et al. 2007), but the role of PEP in mast cell 
functions and and GC action is not fully understood. 
Using PEP+/+ and PEP-/- mice and bone marrow derived mast cells 
(BMMCs) generated from these mice, the current work showed that PEP 
promotes antigen-mediated mast cell inflammatory/allergic response, and yet 
PEP is needed for the antiinflammatory/antiallergic action of GC in mast cells 
(Figure 4.1).  
The finding in the current work that PEP-/- mast cells have reduced response 
to antigen was rather surprising, because deletion of a phosphatase like PEP is 
expected to increase the activity of the kinases it regulates and as such enhance 
mast cell signalling and mast cell action (Kalesnikoff and Galli 2010). This is 
what was observed in human and murine T cells, where overexpression 
experiments and studies in PEP -/- T cells showed that PEP is a negative 
regulator of T cell antigen receptor (TCR) signaling (Hasegawa et al. 2004; 
Brownlie et al. 2012; Bottini and Peterson 2014). Nevetheless, a search through 
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the literature suggests that PEP exhibits cell-type specific responses in murine 
systems. For instance, in B cells, the work of Hasegawa et al. (2004), 
Zikherman et al. (2009) and Dai et al. (2013), showed that BCR (B-cell antigen 
receptor)-induced calcium mobilization, ERK phosphorylation, total tyrosine 
phosphorylation, and proliferation of B cells was not different between 
PEP−/− and PEP+/+ cells B cells. This is different from observations in T cells, 
where deletion of PEP increased the phosphorylation of protein tyrosine 
kinases (PTKs) that activate T cell antigen receptor signalling, leading to 
enhanced proliferation and expansion of effector/memory T cells, as well as 
elevated T cell—dependent Ig (immunoglobulin) production in vivo and in 
vitro  (Hasegawa et al. 2004; Brownlie et al. 2012; Bottini and Peterson 2014), 
meaning that PEP may not be needed for BCR signalling, but is important for 
TCR signalling. 
Interestingly, some other reports suggests that PEP promotes myeloid cell 
(macrophage, dendritic cells, neutrophils) functions. In mouse marcrophages 
and dendritic cells, Wang and colleagues showed that PEP promotes type 1 
IFN (interferon) production after TLR (Toll-like receptor) ligation (Wang et al. 
2013). In addition, a very recent work by Vermeren and colleagues showed 
that PEP is needed for Fc-mediated neutrophil activation, as neutrophil 
effector functions, including production of reactive oxygen species and 
degranulation induced by immobilized immune complexes, were all reduced 
in PEP -/- neutrophils when compared to wild-type neutrophils (Vermeren et 
al. 2016). Since mast cells are also myeloid cells, it is not suprising that PEP 
promotes antigen receptor mediated responses in mast cells, as represented in 
the current work. 
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4.2 PEP PROMOTES ANTIGEN-INDUCED ANAPHYLAXIS 
The current work showed that PEP promotes anaphylaxis, as PEP-/- BALB/c 
mice had reduced anaphylaxis compared to PEP+/+ mice.  
This was unexpected for PEP, since the deletion of PEP is expected to increase 
the activity of protein tyrosine kinases that promote mast cell functions and 
anaphylaxis. One explanation that was thought of, for the current observation, 
was that, PEP exhibits strain specific responses. The reason being that, 
different strains of mice can show differences in immune response, due to 
their different genetic background (Noguchi et al. 2005; Finkelman 2007; 
Rivera et al. 2008). This is common in mast cell related models. For instance, 
the work of Yamashita and colleagues showed that 129/Sv mice were more 
susceptible to anaphylaxis than C57BL/6 mice (Yamashita et al. 2007). 
Furthermore, they showed that the protein tyrosine kinase Lyn is a negative 
regulator of allergic responses contrary to expectation, as mast cells from Lyn 
deficient 129/Sv mice exhibited enhanced degranulation. In contrast, the work 
of Kawakami and colleagues showed that mast cells from Lyn deficient (Lyn-
/-) mice on a mixed C57BL/6 and 129/Sv genetic background exhibited 
normal responses (Kawakami et al. 2000) meaning that some mast cell 
responses may be strain dependent. However, the current observation is in 
agreement with the findings of Obiri et al. (2012), who also showed that PEP is 
a positive regulator of PSA in another mouse train, C57BL/6. This suggests 
that the role of PEP in anaphylaxis is likely independent of the genetic 
background of mice, although its role in immune cell response, differs in 
different cell types. 
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4.3 PEP MODULATES FCRI SIGNALLING TO REGULATE MAST CELL 
FUNCTIONS  
In this work, the cell type specific effect of PEP was analysed by studying its 
role in intracellular calcium (Ca2+i) mobilisation in bone marrow derived 
mast cells (BMMCs). 
Using thapsigargin — a chemical agent that induceds FcRI-independent Ca2+i 
mobilisation — the present study showed that PEP promotes FcRI-mediated 
Ca2+i mobilisation. 
Intracellular calcium (Ca2+i) mobilisation is the central most important 
signalling event that controls exocytotic release of mast cell preformed 
mediators (degranulation), which triggers anaphylaxis in vivo (Ma and 
Beaven 2009; Holowka et al. 2012). Due to the vital role of Ca2+i in antigen 
receptor signalling, analysis of Ca2+i mobilisation is key in the study of 
molecular components that regulate antigen receptor signalling (Feske 2007; 
Vig and Kinet 2009). 
Most of the work to understand how PEP regulates antigen-induced Ca2+ 
mobilisation in immune cells concentrated on lymphocytes (T cells and B cells) 
(Bottini and Peterson 2014). In murine T cells, Hasegawa and colleagues found 
that antigen-induced Ca2+i mobilisation in PEP-/- cells was enhanced, 
compared to control PEP+/+ cells (Hasegawa et al. 2004), but antigen-induced 
Ca2+ mobilisation in B cells did not show any difference between the two cell 
types (Hasegawa et al. 2004; Zikherman et al. 2009; Dai et al. 2013). This shows 
that PEP exhibits cell-type specific response in Ca2+i mobilisation in immune 
cells. It is therefore not surprising that in this analysis PEP-/- BMMCs showed 
reduced Ca2+i mobilisation contrary to what was observed in T and B cells. 
Meaning that whereas PEP is a negative regulator of T cell antigen receptor 
functions, with no effect on B cell antigen receptor signalling (Hasegawa et al. 
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2004; Zikherman et al. 2009; Dai et al. 2013), PEP is a positive regulator of 
antigen-mediated mast cell functions. 
 
Mechanistically, the antigen receptor signalling that mediates Ca2+i 
mobilisation is enhanced by the phosphorylation activities of receptor 
proximal kinases, notably Lck (lymphocyte-specific protein tyrosine kinase) 
(Lyn in mast cells) and Zap-70 (Zeta-chain-associated protein kinase 70) (Syk 
in mast cells) (Gjorloff-Wingren et al. 1999; Hasegawa et al. 2004). PEP gene 
knock-out studies showed that PEP negatively regulates T cell Ca2+i 
mobilisation by antagonising these kinases.  
Although very little is known about the phosphorylation status of these 
kinases in PEP-/- mast cells, a preceding study by Obiri and colleagues 
showed that PEP-/- BMMCs have reduced phosphorylation of PLC 
(phospholipase C-gamma) (Obiri et al. 2012), an enzyme which 
indirectly depends on Lck and Zap-70 phosphorylation activities for its 
activation. In T cells, PEP was shown to regulate Ca2+i mobilisation by 
modulating the phosphorylation of Lck and Zap-70 phosphorylation 
(Hasegawa et al. 2004; Brownlie et al. 2012; Bottini and Peterson 2014). It is 
therefore possible that PEP may regulate Ca2+ mobilisation in activated 
mast cells by modulating the activities of Lck (Lyn in mast cells) and Zap-
70 (Syk in mast cells). 
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4.4 PEP PROMOTES CYTOKINE/CHEMOKINE GENE EXPRESSION IN 
MAST CELLS 
In the present study, gene expression analysis (RNA-seq and qRT-PCR) 
showed that deletion of PEP reduces antigen-induced cytokine/chemokine 
gene expression, suggesting that PEP promotes cytokine/chemokine gene 
expression in activated mast cells. 
The cytokine/chemokine genes whose expression was impaired were TNFα 
(Tumour necrosis factor alpha), IL13 (Interleukin 13) and CSF2/GM-CSF 
(Colony stimulating factor 2/Granulocyte-macrophage colony-stimulating 
factor). TNFα promotes neutrophil recruitment (Nakae et al. 2007b) and 
dendritic cell migration (Suto et al. 2006). It also promotes bacterial clearance 
in sepsis (Malaviya et al. 1996; Piliponsky et al. 2010) and induces airway 
hyperresponsiveness (AHR), lung inflammation, and Th2 (T helper 2) 
cytokine production in asthma (Nakae et al. 2007a). IL13 is well known to be 
a potent inducer of allergic asthma (Grunig et al. 1998; Zhu et al. 1999; Wynn 
2003; Akdis et al. 2011), whereas CSF2 is an important growth factor of 
immune cells (Wodnar-Filipowicz et al. 1989). These genes are key regulators 
of mast cell allergic response (Kalesnikoff and Galli 2010; Reber and Frossard 
2014), showing that PEP plays an important role in mast cell-mediated 
allergic inflammation. 
 
The expression of these cytokine/chemokine genes is regulated by major 
transcription factors (TFs) that belong to the NFB (Nuclear factor B), AP1 
(Activator protein 1) and NFAT (Nuclear factor of activated T cells) families 
(Marquardt and Walker 2000; Klein et al. 2006).  
In the current project, the expression of two genes, FOS and JUND which are 
subunits of the AP-1 family of TFs (Wisdom 1999; Mechta-Grigoriou et al. 
2001; Hess et al. 2004) were found to be higher in activated PEP-/- BMMCs.  
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Varoius subunits of AP-1 form dimeric TFs that differ in activity, in the 
regulation of target gene expression (Wisdom 1999; Mechta-Grigoriou et al. 
2001; Hess et al. 2004). In the context of cytokine gene expression, JUND 
dimers are known to be less potent transcriptional activators, and hence can 
repress cytokine/chemokine gene expression (Meixner et al. 2004). It is 
therefore possible that increased JUND levels in activated PEP-/- BMMCs 
resulted in increased JUND dimer formation, which resulted in the repression 
of antigen-induced cytokine/chemokine gene expression. 
 
Additionally, genes belonging to the family of dual-specificity phosphatases 
(DUSPs) were also found to be upregulated in PEP-/- BMMCs. A number of 
these DUSPs (DUSP1, DUSP4, DUSP5, DUSP8) negatively regulate MAPKs 
such as ERK1/2, p38 MAPK and JNK (Keyse 2000; Clark and Lasa 2003; 
Dickinson and Keyse 2006), which regulate the activation of NFB, AP1 and 
NFAT transcription factors (Karin et al. 1997; Schulze-Osthoff et al. 1997; Wu 
et al. 2003). Hence, increased DUSPs activity can lead to reduced 
transcription factor activation and contribute to the reduced 
cytokine/chemokine gene expression in activated PEP-/- BMMCs. 
 
Moreover, cytokine gene expression is also regulated by Ca2+i. A number of 
TFs that regulate cytokine/chemokine gene expression are regulated by 
signalling pathways that depend directly or indirectly on Ca2+i mobilisation 
(Hogan et al. 2003; Feske 2007; Baba et al. 2008). In this work, PEP-/- BMMCs 
showed reduced Ca2+i mobilisation, which can lead to reduced activation of 
TFs such as NFATc (Hogan et al. 2003; Feske 2007) and contribute to the 
reduced cytokine/chemokine gene expression in PEP-/- BMMCs.  
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4.5 PEP PROMOTES ANTIGEN-INDUCED PTGS2/COX-2 GENE 
EXPRESSION IN MAST CELLS 
Another finding from the current work is that PEP promotes antigen-induced 
PTGS2/COX-2 gene expression in mast cells, as PEP-/- BMMCs showed 
reduced PTGS2/COX-2 expression compared to PEP+/+ cells. 
 
Prostaglandin synthases (PTGS) also known as cyclooxygenases (COX) 
convert arachidonic acid (AA) released from membrane phospholipids by 
phospholipases to prostaglandin H2 (PGH2), which is then converted to 
various prostanoids (prostaglandins, prostacyclin and thromboxanes) 
(Firestein et al. 2015; Rumzhum and Ammit 2016).  
There are two major isoforms of PTGS/COX expressed in most cells, 
PTGS1/COX-1 and PTGS2/COX-2 (DeWitt 1991; Firestein et al. 2015). Of the 
two isoforms, COX-1 is constitutively expressed at high levels in some cells 
(e.g. endothelium, renal tubules, platelets), to maintain basal level prostanoid, 
for normal physiological regulation. On the other hand, COX-2, which is 
induced by a wide range of stimuli in most cells, is the key enzyme for 
prostanoid synthesis in response to immune cell activation (Firestein et al. 
2015; Rumzhum and Ammit 2016), including mast cell activation (Reddy et al. 
2000; Boyce 2007). As the downstream products of COX-2 (prostaglandins, 
prostacyclin and thromboxanes) promote inflammation (Firestein et al. 2015), 
inhibition of COX-2 activity is a key mechanism of the commonly used 
antiinflammatory drugs (non-steroidal antiinflammatory drugs (NSAIDs) 
such as aspirin, and steroidal antiinflammatory glucocorticoids, such as 
dexamethasone) (Goulding 2004; Hayashi et al. 2004; Fendrick and Greenberg 
2009; Candido et al. 2017).  
In mast cells, the COX-2 gene promoter was shown to contain transcriptional 
regulatory elements for AP-1, C/EBPβ (CAAT Enhancer Binding Protein Beta), 
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CRE (cyclic AMP response elements) and NF-IL6 (nuclear factor for 
interleukin 6 expression) (Reddy et al. 2000). Moreover MAPK signalling was 
found to be important for transcriptional regulation of these transcriptional 
regulatory elements (Reddy et al. 2000). In the current study, RNA-seq 
analysis showed that MAPK pathway was the most significantly misregulated 
pathway in PEP-/- BMMCs. It is thefore possible that changes in MAPK 
signalling in PEP-/- BMMCs contributed to the reduced COX-2 gene 
expression in activated PEP-/- BMMCs. 
 
4.6 PEP IS NEEDED FOR GLUCOCORTICOID-INDUCED NEGATIVE 
REGULATION OF PTGS2/COX-2 GENE EXPRESSION IN MAST 
CELLS 
The results from this work showed that PEP is needed for glucocorticoid (GC)-
induced negative regulation of COX-2 expression in mast cells. 
 
COX-2 is a proinflammatory enzyme whose expression is greatly elevated in 
response to inflammatory stimuli (Mitchell et al. 1995; Herschman 1996; Kang 
et al. 2007; Rumzhum and Ammit 2016). It is the rate-limiting enzyme in the 
de novo synthesis of the prostanoid family of eicosanoids (prostaglandins, 
prostacyclin and thromboxanes) (Kang et al. 2007; Rumzhum and Ammit 
2016). Prostanoids such as PGD2 (prostaglandin D2), LTB4 (leukotriene B4) 
and LTC4 (leukotriene C4), which are released by activated mast cells, 
contribute to increased bronchoconstriction, vascular permeability, 
recruitment of leukocyte, mucus production, and nerve cell activation 
associated with allergic conditions such as asthma and anaphylaxis (Galli et 
al. 2005; Weller et al. 2007). Consequently, inhibition of COX-2 gene 
expression is a major mechanism by which GCs exert their therapeutic effects 
(Goulding 2004; Hayashi et al. 2004). The current finding that the ability of 
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GC to inhibit COX-2 gene expression is lost in PEP-/- BMMCs, shows that PEP 
is needed for antiinflammatory response by GCs.  
 
In the current work, the gene expression profile from RNA-Seq analysis did 
show that apart from COX-2, deletion of PEP induced changes in the GC 
response to many other genes. Although these other genes did not mapped 
unto any signalling pathway of interest, changes in their expression does show 
that PEP induces widespread perturbations in GC-induced gene regulation. 
These as-yet-unknown perturbations could have contributed to the impaired 
GC response in the regulation of COX-2 gene expression in activated PEP-/- 
BMMCs. 
 
4.7 PEP MODULATES GLUCOCORTICOID-INDUCED REGULATION OF 
PTGDS/L-PGDS GENE EXPRESSION IN MAST CELLS 
In addition to impaired GC mediated regulation of COX-2 gene expression, 
the present work also showed that the ability of GCs to regulate another gene 
involved in the arachidonic acid pathway, PTGDS (prostaglandin D2 
synthase) also called L-PGDS (lipocalin-type prostaglandin D2 synthase) was 
impaired. In this case, GCs induced PTGDS gene expression in mast cells, an 
effect that was enhanced upon PEP gene deletion. 
 
There are two isoforms of prostaglandin D2 synthases, PTGDS and another 
synthase, H-PGDS (hematopoietic prostaglandin D2 synthase). They are the 
terminal enzymes that specifically catalyse the synthesis of PGD2 
(prostaglandin D2) from arachidonic acid metabolites (Helliwell et al. 2004; 
Boyce 2007; Firestein et al. 2015). 
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H-PGDS is responsible for the formation of PGD2 in immune cells such as mast 
cells (Helliwell et al. 2004; Boyce 2007; Firestein et al. 2015), while PTGDS, 
whose regulation by GC was impaired, as represented in the current results, 
functions in brain tissues, such as neurons (Urade et al. 1985; Urade and 
Hayaishi 1999).  
Studies with neuronal cells have shown that the PTGDS gene promoter has 
response elements for thyroid hormone (TRE) (Garcı́a-Fernández et al. 1998), 
estrogen (ERE) and glucocorticoids (GRE) (Garcia-Fernandez et al. 2000). It is 
therefore not surprising that PTGDS expression was upregulated by GCs in 
mast cells. However, since PTGDS has no known role in the synthesis of 
prostaglandins in immune cells such as mast cells, the implication of the 
enhanced GC-induced PTGDS expression in PEP-/- BMMCs cannot be easily 
deduced. 
 
4.8 PEP MODULATES MAST CELL FUNCTION AND GLUCOCORTICOID 
ACTION VIA ITS PHOSPHATASE ACTIVITY 
Gene knockout models as used in this work are useful tools for studying 
gene function (Alberts et al. 2008). However, complete gene knock-out 
suffers from the failure to delineate gene specific changes from secondary 
effects caused by the knock-out (Sudhof 2004; Knight and Shokat 2007). 
Strategies that helps to delineate primary effects from secondary responses 
include, the use of chemical inhibitors of the protein product of the targeted 
gene (Sudhof 2004; Knight and Shokat 2007). 
Using PEP activity inhibitor (L75NO4), the present work showed that PEP 
modulates FcRI-mediated mast cell functions and GC action via its 
phosphatase activities, just as was observed for the PEP gene knock-out 
studies in this work. 
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A number of groups have shown that PEP can be targeted with 
chemical/pharmacological inhibitors in vivo (Obiri et al. 2012; He et al. 2013) 
and in vitro (Yu et al. 2007; Stanford et al. 2011; He et al. 2013). Of much 
interest to the current work, are the findings of Obiri et al (2012) and He et al 
(2013). Using a gold (I) phosphine complex (named C28), Obiri and colleagues 
showed that PEP regulates anaphylaxis, and that PEP is needed for GC action 
in vivo (Obiri et al. 2012). On the other, He and colleagues used the present 
inhibitor (L75NO4) - a benzofuran salicylic acid-based compound, which is 
chemically more specific inhibitor of PEP activity than C28, to show that PEP 
is a positive regulator of anaphylaxis (He et al. 2013). The findings from these 
two groups duely confirm the current observation that PEP modulates mast 
cell functions and the GC response in mast cells via its phosphatase activities. 
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CONCLUSION 
The present work revealed that the role of PEP in anaphylaxis is not strain 
specific, showing that PEP is an essential modulator of anaphylaxis. 
Furthermore, it was found that PEP is needed for FcRI (antigen receptor)-
mediated Ca2+i mobilisation, cytokine/chemokine and COX-2 gene 
expression, meaning that PEP is a positive regulator of mast cell effector 
functions. Nevertheless, it was also found that PEP is needed for GC-induced 
negative regulation of COX-2 gene expression. These effects were mediated 
via PEP activity, showing that PEP is directly involved in the regulation of 
mast cell functions and GC action. 
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Figure 4.1 PEP is needed for mast cell function and glucocorticoid action. (A) In PEP+/+ BMMCs, 
crosslinking of IgE-bound FcRI receptors by antigen activates proinflammatory signalling events that 
results in elevation of intracellular calcium Ca2+i, increased cytokine/chemokine gene expression and 
increased expression of COX-2, all of which contribute to allergy/anaphylaxis. (B) In PEP-/- cells, there 
is reduced activation of these proinflammatory signalling events and loss of GC-induced negative 
regulation of COX-2 gene expression (current work), which may contribute to impaired GC action in 
allergy/anaphylaxis as reported by Obiri et al. (2012). 
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